{ "name": "GLP-1 Briefing: readouts", "description": "Every tracked GLP-1 and incretin trial with a sponsor-filed primary completion date, upcoming and lapsed.", "source": "https://glp1briefing.com", "documentation": "https://glp1briefing.com/llms.txt", "license": "CC BY 4.0", "license_url": "https://creativecommons.org/licenses/by/4.0/", "attribution": "GLP-1 Briefing (https://glp1briefing.com)", "generated": "2026-10-19T10:10:49+00:00", "count": 320, "fields": { "nct_id": "ClinicalTrials.gov identifier.", "state": "upcoming = date still ahead. reached = date passed and the sponsor filed it as actual. overdue = date passed while still marked estimated, and nobody has refiled.", "primary_completion_date": "As filed. May be a month rather than a day.", "primary_completion_type": "ACTUAL or ESTIMATED, as filed.", "drug": "INN of the molecule.", "phase": "Trial phase as filed.", "status": "Recruitment status as filed.", "enrollment": "Participants, actual or planned.", "sponsor": "Lead sponsor as filed.", "title": "Official title as filed.", "primary_outcome": "The sponsor's own wording.", "record_url": "The registry record." }, "readouts": [ { "nct_id": "NCT06297603", "state": "upcoming", "primary_completion_date": "2026-10", "primary_completion_type": "ESTIMATED", "drug": "retatrutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "320", "sponsor": "Eli Lilly and Company", "title": "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c) (%)", "record_url": "https://clinicaltrials.gov/study/NCT06297603" }, { "nct_id": "NCT05119179", "state": "upcoming", "primary_completion_date": "2026-10-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "300", "sponsor": "The University of Texas Health Science Center, Houston", "title": "Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes", "primary_outcome": "Mean change in beta cell responsivity", "record_url": "https://clinicaltrials.gov/study/NCT05119179" }, { "nct_id": "NCT06662383", "state": "upcoming", "primary_completion_date": "2026-11", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "800", "sponsor": "Eli Lilly and Company", "title": "A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity", "primary_outcome": "Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT06662383" }, { "nct_id": "NCT06962280", "state": "upcoming", "primary_completion_date": "2026-11", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "465", "sponsor": "Eli Lilly and Company", "title": "A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06962280" }, { "nct_id": "NCT06914895", "state": "upcoming", "primary_completion_date": "2026-11", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "905", "sponsor": "Eli Lilly and Company", "title": "A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06914895" }, { "nct_id": "NCT07431086", "state": "upcoming", "primary_completion_date": "2026-11-13", "primary_completion_type": "ESTIMATED", "drug": "olatorepatide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "120", "sponsor": "Regeneron Pharmaceuticals", "title": "Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US", "primary_outcome": "Occurrence of Treatment-Emergent Adverse Events (TEAEs)", "record_url": "https://clinicaltrials.gov/study/NCT07431086" }, { "nct_id": "NCT06716216", "state": "upcoming", "primary_completion_date": "2026-11-14", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "537", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "title": "A Study of BGM0504 in Participants With Type 2 Diabetes", "primary_outcome": "Change From Baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06716216" }, { "nct_id": "NCT06577090", "state": "upcoming", "primary_completion_date": "2026-11-20", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "136", "sponsor": "Skye Bioscience, Inc.", "title": "Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo", "primary_outcome": "Percent change in body weight (main study)", "record_url": "https://clinicaltrials.gov/study/NCT06577090" }, { "nct_id": "NCT07059377", "state": "upcoming", "primary_completion_date": "2026-12", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "100", "sponsor": "Ottawa Heart Institute Research Corporation", "title": "Semaglutide for Smoking Cessation in Patients With Diabetes", "primary_outcome": "Project success", "record_url": "https://clinicaltrials.gov/study/NCT07059377" }, { "nct_id": "NCT07128082", "state": "upcoming", "primary_completion_date": "2026-12", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "1000", "sponsor": "Scripps Translational Science Institute", "title": "The Long COVID Treatment Trial", "primary_outcome": "Primary Objective 1: Changes in fatigue severity score, measured by Fatigue Severity Scale (FSS)", "record_url": "https://clinicaltrials.gov/study/NCT07128082" }, { "nct_id": "NCT07446439", "state": "upcoming", "primary_completion_date": "2026-12-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "280", "sponsor": "Vanda Pharmaceuticals", "title": "A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use", "primary_outcome": "Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary.", "record_url": "https://clinicaltrials.gov/study/NCT07446439" }, { "nct_id": "NCT07139548", "state": "upcoming", "primary_completion_date": "2026-12-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "600", "sponsor": "Guangdong Raynovent Biotech Co., Ltd", "title": "A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes", "primary_outcome": "Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg)", "record_url": "https://clinicaltrials.gov/study/NCT07139548" }, { "nct_id": "NCT07487103", "state": "upcoming", "primary_completion_date": "2026-12", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "478", "sponsor": "Qilu Pharmaceutical Co., Ltd.", "title": "Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes", "primary_outcome": "Change in HbA1c", "record_url": "https://clinicaltrials.gov/study/NCT07487103" }, { "nct_id": "NCT06778967", "state": "upcoming", "primary_completion_date": "2026-12-11", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "1100", "sponsor": "Gan & Lee Pharmaceuticals.", "title": "A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c)(%)", "record_url": "https://clinicaltrials.gov/study/NCT06778967" }, { "nct_id": "NCT07223242", "state": "upcoming", "primary_completion_date": "2026-12-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2/P3", "status": "RECRUITING", "enrollment": "120", "sponsor": "University of Texas Southwestern Medical Center", "title": "Tailored Exercise Training Study Among Adults With HFpEF", "primary_outcome": "Peak Exercise Oxygen Uptake (VO2peak)", "record_url": "https://clinicaltrials.gov/study/NCT07223242" }, { "nct_id": "NCT06802081", "state": "upcoming", "primary_completion_date": "2026-12-31", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "RECRUITING", "enrollment": "100", "sponsor": "The Cleveland Clinic", "title": "TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation", "primary_outcome": "AFib burden", "record_url": "https://clinicaltrials.gov/study/NCT06802081" }, { "nct_id": "NCT05173714", "state": "upcoming", "primary_completion_date": "2026-12-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "156", "sponsor": "Srinvasan Beddhu", "title": "Sit Less, Interact and Move More (SLIMM) 2 Study", "primary_outcome": "Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization", "record_url": "https://clinicaltrials.gov/study/NCT05173714" }, { "nct_id": "NCT06959784", "state": "upcoming", "primary_completion_date": "2026-12-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "ENROLLING_BY_INVITATION", "enrollment": "142", "sponsor": "China-Japan Friendship Hospital", "title": "Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)", "primary_outcome": "Cardiovascular and cerebrovascular event risk score", "record_url": "https://clinicaltrials.gov/study/NCT06959784" }, { "nct_id": "NCT06005012", "state": "upcoming", "primary_completion_date": "2026-12-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "120", "sponsor": "University of California, San Diego", "title": "Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM", "primary_outcome": "Change in fibrosis due to NAFLD", "record_url": "https://clinicaltrials.gov/study/NCT06005012" }, { "nct_id": "NCT07165158", "state": "upcoming", "primary_completion_date": "2026-12-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "150", "sponsor": "The First Affiliated Hospital of Xiamen University", "title": "The Effect of Semaglutide on Bone Health", "primary_outcome": "lumbar bone mineral density", "record_url": "https://clinicaltrials.gov/study/NCT07165158" }, { "nct_id": "NCT06884293", "state": "upcoming", "primary_completion_date": "2026-12-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "479", "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "title": "A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease \uff08MAFLD\uff09", "primary_outcome": "percentage change in body weight from baseline", "record_url": "https://clinicaltrials.gov/study/NCT06884293" }, { "nct_id": "NCT07297589", "state": "upcoming", "primary_completion_date": "2027-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "136", "sponsor": "Instituto Mexicano del Seguro Social", "title": "Epicardial Cardiac Fat-CT (EPIC-CT)", "primary_outcome": "Epicardial fat", "record_url": "https://clinicaltrials.gov/study/NCT07297589" }, { "nct_id": "NCT06858839", "state": "upcoming", "primary_completion_date": "2027-01-21", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "3853", "sponsor": "Amgen", "title": "Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight", "primary_outcome": "Percent Change From Baseline in Body Weight at Week 72", "record_url": "https://clinicaltrials.gov/study/NCT06858839" }, { "nct_id": "NCT06858878", "state": "upcoming", "primary_completion_date": "2027-01-21", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "1105", "sponsor": "Amgen", "title": "Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight", "primary_outcome": "Percent Change from Baseline in Body Weight at Week 72", "record_url": "https://clinicaltrials.gov/study/NCT06858878" }, { "nct_id": "NCT07724340", "state": "upcoming", "primary_completion_date": "2027-02", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "150", "sponsor": "Antag Therapeutics", "title": "A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity", "primary_outcome": "Body weight", "record_url": "https://clinicaltrials.gov/study/NCT07724340" }, { "nct_id": "NCT06672549", "state": "upcoming", "primary_completion_date": "2027-02", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "RECRUITING", "enrollment": "125", "sponsor": "Eli Lilly and Company", "title": "A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)", "primary_outcome": "Number of Participants Allocated to Each ISA", "record_url": "https://clinicaltrials.gov/study/NCT06672549" }, { "nct_id": "NCT07521631", "state": "upcoming", "primary_completion_date": "2027-02-04", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "RECRUITING", "enrollment": "372", "sponsor": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.", "title": "Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes", "primary_outcome": "Primary Outcome", "record_url": "https://clinicaltrials.gov/study/NCT07521631" }, { "nct_id": "NCT07481747", "state": "upcoming", "primary_completion_date": "2027-02-14", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P3", "status": "RECRUITING", "enrollment": "2539", "sponsor": "Hudson Biotech", "title": "Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)", "primary_outcome": "Mean percent change in body weight from randomization", "record_url": "https://clinicaltrials.gov/study/NCT07481747" }, { "nct_id": "NCT07073417", "state": "upcoming", "primary_completion_date": "2027-02-27", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "163", "sponsor": "Hangzhou Sciwind Biosciences Co., Ltd.", "title": "A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)", "primary_outcome": "Percentage change in body weight relative to baseline", "record_url": "https://clinicaltrials.gov/study/NCT07073417" }, { "nct_id": "NCT07101939", "state": "upcoming", "primary_completion_date": "2027-03", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "120", "sponsor": "Actimed Therapeutics Ltd", "title": "A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)", "primary_outcome": "The change in lean body mass (LBM) in patients receiving one of two doses of ACM-001.1 whilst also receiving semaglutide.", "record_url": "https://clinicaltrials.gov/study/NCT07101939" }, { "nct_id": "NCT07285902", "state": "upcoming", "primary_completion_date": "2027-03", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "572", "sponsor": "Fujian Shengdi Pharmaceutical Co., Ltd.", "title": "A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity", "primary_outcome": "Percentage change from baseline in body weight after 52 weeks of treatment", "record_url": "https://clinicaltrials.gov/study/NCT07285902" }, { "nct_id": "NCT07011667", "state": "upcoming", "primary_completion_date": "2027-03-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "609", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term", "primary_outcome": "Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07011667" }, { "nct_id": "NCT07801820", "state": "upcoming", "primary_completion_date": "2027-03", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "240", "sponsor": "Shanghai Minwei Biotechnology Co., Ltd", "title": "Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus", "primary_outcome": "Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 20 Compared to Placebo", "record_url": "https://clinicaltrials.gov/study/NCT07801820" }, { "nct_id": "NCT07467447", "state": "upcoming", "primary_completion_date": "2027-03-14", "primary_completion_type": "ESTIMATED", "drug": "retatrutide", "phase": "P2", "status": "RECRUITING", "enrollment": "300", "sponsor": "Hudson Biotech", "title": "Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight", "primary_outcome": "Mean percent change in body weight from randomization/baseline to Week 24.", "record_url": "https://clinicaltrials.gov/study/NCT07467447" }, { "nct_id": "NCT06606821", "state": "upcoming", "primary_completion_date": "2027-03-20", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "RECRUITING", "enrollment": "124", "sponsor": "Tina Vilsb\u00f8ll", "title": "The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease", "primary_outcome": "Lipid core burden index", "record_url": "https://clinicaltrials.gov/study/NCT06606821" }, { "nct_id": "NCT07156539", "state": "upcoming", "primary_completion_date": "2027-03-30", "primary_completion_type": "ESTIMATED", "drug": "dulaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "546", "sponsor": "Jiangsu Hansoh Pharmaceutical Co., Ltd.", "title": "A Phase 3 Study of HS-20094 in Patients With T2DM", "primary_outcome": "Change in HbA1c", "record_url": "https://clinicaltrials.gov/study/NCT07156539" }, { "nct_id": "NCT06361238", "state": "upcoming", "primary_completion_date": "2027-03-31", "primary_completion_type": "ESTIMATED", "drug": "liraglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "260", "sponsor": "The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School", "title": "Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery", "primary_outcome": "The incidence of delirium", "record_url": "https://clinicaltrials.gov/study/NCT06361238" }, { "nct_id": "NCT07483801", "state": "upcoming", "primary_completion_date": "2027-04", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "112", "sponsor": "Cambridge University Hospitals NHS Foundation Trust", "title": "DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies", "primary_outcome": "Sub-study 1A:Change in forearm blood flow parameters after infusion of semaglutide (Ratio)", "record_url": "https://clinicaltrials.gov/study/NCT07483801" }, { "nct_id": "NCT07537088", "state": "upcoming", "primary_completion_date": "2027-04", "primary_completion_type": "ESTIMATED", "drug": "dulaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "468", "sponsor": "First Affiliated Hospital of Wannan Medical College", "title": "Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease", "primary_outcome": "Urine Albumin-to-Creatinine Ratio\uff08UACR\uff09", "record_url": "https://clinicaltrials.gov/study/NCT07537088" }, { "nct_id": "NCT07843862", "state": "upcoming", "primary_completion_date": "2027-04", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "240", "sponsor": "Fujian Shengdi Pharmaceutical Co., Ltd.", "title": "A Study of HRS-4729 Injection in Participants With Type 2 Diabetes", "primary_outcome": "Change From Baseline in HbA1c", "record_url": "https://clinicaltrials.gov/study/NCT07843862" }, { "nct_id": "NCT06184633", "state": "upcoming", "primary_completion_date": "2027-04-10", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "280", "sponsor": "Rijnstate Hospital", "title": "DUTCH Weight Control in Atrial Fibrillation Study", "primary_outcome": "The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome", "record_url": "https://clinicaltrials.gov/study/NCT06184633" }, { "nct_id": "NCT06987695", "state": "upcoming", "primary_completion_date": "2027-04-27", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "279", "sponsor": "Amgen", "title": "Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease", "primary_outcome": "Percent Change From Baseline in Body Weight at Week 72", "record_url": "https://clinicaltrials.gov/study/NCT06987695" }, { "nct_id": "NCT06854614", "state": "upcoming", "primary_completion_date": "2027-04-28", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "150", "sponsor": "The Cleveland Clinic", "title": "Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)", "primary_outcome": "Weight change", "record_url": "https://clinicaltrials.gov/study/NCT06854614" }, { "nct_id": "NCT05586802", "state": "upcoming", "primary_completion_date": "2027-04-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "150", "sponsor": "Georgios Papadakis", "title": "Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome", "primary_outcome": "Design 1 : sperm retrieval rate at mTESE biopsy", "record_url": "https://clinicaltrials.gov/study/NCT05586802" }, { "nct_id": "NCT07466017", "state": "upcoming", "primary_completion_date": "2027-04-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "130", "sponsor": "Cascade Pharmaceuticals, Inc", "title": "A Study of CS060380 Tablets in Patients With MASH and Obesity", "primary_outcome": "Percentage change in liver fat content from baseline to Week 36 (MRI-PDFF)", "record_url": "https://clinicaltrials.gov/study/NCT07466017" }, { "nct_id": "NCT06548490", "state": "upcoming", "primary_completion_date": "2027-04-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "200", "sponsor": "Milton S. Hershey Medical Center", "title": "GLP-1R Agonist Treatment for Opioid Use Disorder", "primary_outcome": "Number of participants being abstinent from illicit and nonprescribed opioids.", "record_url": "https://clinicaltrials.gov/study/NCT06548490" }, { "nct_id": "NCT07064486", "state": "upcoming", "primary_completion_date": "2027-04-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "152", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "title": "A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia", "primary_outcome": "Change From Baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT07064486" }, { "nct_id": "NCT05356104", "state": "upcoming", "primary_completion_date": "2027-05", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "110", "sponsor": "Chinese University of Hong Kong", "title": "GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)", "primary_outcome": "Change of Brain Peak Width of Skeletonized Mean Diffusivity", "record_url": "https://clinicaltrials.gov/study/NCT05356104" }, { "nct_id": "NCT07613307", "state": "upcoming", "primary_completion_date": "2027-05", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "RECRUITING", "enrollment": "130", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting", "primary_outcome": "Change from Baseline in Hemoglobin A1C (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT07613307" }, { "nct_id": "NCT06191848", "state": "upcoming", "primary_completion_date": "2027-05", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "352", "sponsor": "University of Melbourne", "title": "Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)", "primary_outcome": "Percentage of patients who undergo knee replacement in the target joint", "record_url": "https://clinicaltrials.gov/study/NCT06191848" }, { "nct_id": "NCT06897475", "state": "upcoming", "primary_completion_date": "2027-05", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "200", "sponsor": "Eli Lilly and Company", "title": "A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06897475" }, { "nct_id": "NCT06931028", "state": "upcoming", "primary_completion_date": "2027-05-07", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P3", "status": "RECRUITING", "enrollment": "260", "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "title": "A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI\u226528 kg/m2", "primary_outcome": "Change from Baseline in Apnea-Hypopnea Index (AHI)", "record_url": "https://clinicaltrials.gov/study/NCT06931028" }, { "nct_id": "NCT07220642", "state": "upcoming", "primary_completion_date": "2027-05-11", "primary_completion_type": "ESTIMATED", "drug": "cagrilintide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "300", "sponsor": "Novo Nordisk A/S", "title": "Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide", "primary_outcome": "Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07220642" }, { "nct_id": "NCT07220759", "state": "upcoming", "primary_completion_date": "2027-05-12", "primary_completion_type": "ESTIMATED", "drug": "cagrilintide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "330", "sponsor": "Novo Nordisk A/S", "title": "Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide", "primary_outcome": "Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07220759" }, { "nct_id": "NCT07745504", "state": "upcoming", "primary_completion_date": "2027-05-18", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "285", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight", "primary_outcome": "Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07745504" }, { "nct_id": "NCT06003153", "state": "upcoming", "primary_completion_date": "2027-05-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "125", "sponsor": "Massachusetts General Hospital", "title": "GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH", "primary_outcome": "Insulin response to oral semaglutide treatment", "record_url": "https://clinicaltrials.gov/study/NCT06003153" }, { "nct_id": "NCT07777575", "state": "upcoming", "primary_completion_date": "2027-05-31", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "RECRUITING", "enrollment": "150", "sponsor": "Technical University of Munich", "title": "Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide", "primary_outcome": "Change in contractile thigh muscle volume (mL), as assessed by magnetic resonance imaging (MRI)", "record_url": "https://clinicaltrials.gov/study/NCT07777575" }, { "nct_id": "NCT07411378", "state": "upcoming", "primary_completion_date": "2027-06", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "164", "sponsor": "Biophytis", "title": "Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.", "primary_outcome": "Change from baseline in the knee extension strength at 21 weeks", "record_url": "https://clinicaltrials.gov/study/NCT07411378" }, { "nct_id": "NCT07817251", "state": "upcoming", "primary_completion_date": "2027-06-09", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "210", "sponsor": "Novo Nordisk A/S", "title": "Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema", "primary_outcome": "Number of treatment emergent adverse events (TEAEs)", "record_url": "https://clinicaltrials.gov/study/NCT07817251" }, { "nct_id": "NCT07639021", "state": "upcoming", "primary_completion_date": "2027-06-14", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "233", "sponsor": "Novo Nordisk A/S", "title": "A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity", "primary_outcome": "Number of gastrointestinal adverse events", "record_url": "https://clinicaltrials.gov/study/NCT07639021" }, { "nct_id": "NCT07871409", "state": "upcoming", "primary_completion_date": "2027-06-16", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "230", "sponsor": "Amgen", "title": "Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight", "primary_outcome": "Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home Administration", "record_url": "https://clinicaltrials.gov/study/NCT07871409" }, { "nct_id": "NCT07150975", "state": "upcoming", "primary_completion_date": "2027-06-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "420", "sponsor": "Gan & Lee Pharmaceuticals.", "title": "Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy\u00ae) in Adult Obese or Overweight Subjects", "primary_outcome": "Percentage change in body weight from baseline after 52 weeks (W) of treatment.", "record_url": "https://clinicaltrials.gov/study/NCT07150975" }, { "nct_id": "NCT07307235", "state": "upcoming", "primary_completion_date": "2027-06-30", "primary_completion_type": "ESTIMATED", "drug": "lixisenatide", "phase": "P4", "status": "RECRUITING", "enrollment": "1316", "sponsor": "Shanghai Zhongshan Hospital", "title": "Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents", "primary_outcome": "hemoglobin A1c (HbA1c) change", "record_url": "https://clinicaltrials.gov/study/NCT07307235" }, { "nct_id": "NCT07173712", "state": "upcoming", "primary_completion_date": "2027-06-30", "primary_completion_type": "ESTIMATED", "drug": "lixisenatide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "324", "sponsor": "Yanbing Li", "title": "Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes", "primary_outcome": "Proportion of subjects with optimal glycemic control", "record_url": "https://clinicaltrials.gov/study/NCT07173712" }, { "nct_id": "NCT07438444", "state": "upcoming", "primary_completion_date": "2027-07", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "344", "sponsor": "Eli Lilly and Company", "title": "A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity", "primary_outcome": "Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration", "record_url": "https://clinicaltrials.gov/study/NCT07438444" }, { "nct_id": "NCT07017270", "state": "upcoming", "primary_completion_date": "2027-07", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "100", "sponsor": "Unity Health Toronto", "title": "Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis", "primary_outcome": "Adherence of Study Intervention", "record_url": "https://clinicaltrials.gov/study/NCT07017270" }, { "nct_id": "NCT06803888", "state": "upcoming", "primary_completion_date": "2027-07-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "140", "sponsor": "Ali Aminian", "title": "Bariatric Surgery vs. Semaglutide vs. Tirzepatide", "primary_outcome": "Mean percentage total body weight loss at Week 52", "record_url": "https://clinicaltrials.gov/study/NCT06803888" }, { "nct_id": "NCT07232719", "state": "upcoming", "primary_completion_date": "2027-07", "primary_completion_type": "ESTIMATED", "drug": "retatrutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "250", "sponsor": "Eli Lilly and Company", "title": "A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight", "primary_outcome": "Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT07232719" }, { "nct_id": "NCT07104383", "state": "upcoming", "primary_completion_date": "2027-07-01", "primary_completion_type": "ESTIMATED", "drug": "VK2735", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "1100", "sponsor": "Viking Therapeutics, Inc.", "title": "VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)", "primary_outcome": "Percent change in body weight from baseline to Week 78 in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07104383" }, { "nct_id": "NCT07104500", "state": "upcoming", "primary_completion_date": "2027-07-01", "primary_completion_type": "ESTIMATED", "drug": "VK2735", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "4500", "sponsor": "Viking Therapeutics, Inc.", "title": "VK2735 for Weight Management Phase 3", "primary_outcome": "Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment", "record_url": "https://clinicaltrials.gov/study/NCT07104500" }, { "nct_id": "NCT07046819", "state": "upcoming", "primary_completion_date": "2027-07-30", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "RECRUITING", "enrollment": "120", "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", "title": "Tirzepatide in MetALD", "primary_outcome": "Metabolic improvement from baseline as measured by percentage reduction of body weight and reduction in liver steatosis from baseline as measured by percentage reduction in Fibroscan controlled attenuation parameter (CAP) score.", "record_url": "https://clinicaltrials.gov/study/NCT07046819" }, { "nct_id": "NCT07030621", "state": "upcoming", "primary_completion_date": "2027-07-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "436", "sponsor": "RenJi Hospital", "title": "Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial", "primary_outcome": "mRS at 90-days", "record_url": "https://clinicaltrials.gov/study/NCT07030621" }, { "nct_id": "NCT06993792", "state": "upcoming", "primary_completion_date": "2027-08", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "1400", "sponsor": "Eli Lilly and Company", "title": "A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes", "primary_outcome": "Number of Participants Allocated to Each Study", "record_url": "https://clinicaltrials.gov/study/NCT06993792" }, { "nct_id": "NCT06972472", "state": "upcoming", "primary_completion_date": "2027-08", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "600", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06972472" }, { "nct_id": "NCT06972459", "state": "upcoming", "primary_completion_date": "2027-08", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "800", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity", "primary_outcome": "Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT06972459" }, { "nct_id": "NCT06864026", "state": "upcoming", "primary_completion_date": "2027-08", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "200", "sponsor": "Eli Lilly and Company", "title": "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)", "primary_outcome": "Percentage of Participants Achieving Normalized Functioning Health Assessment Questionnaire - Disability Index (HAQ-DI) \u22640.5 at 12 Months of Therapy", "record_url": "https://clinicaltrials.gov/study/NCT06864026" }, { "nct_id": "NCT07588438", "state": "upcoming", "primary_completion_date": "2027-08-10", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "RECRUITING", "enrollment": "160", "sponsor": "Las R\u00edas Medical Center", "title": "Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.", "primary_outcome": "Mean Percent Change From Baseline in Body Weight at 52 Weeks.", "record_url": "https://clinicaltrials.gov/study/NCT07588438" }, { "nct_id": "NCT06732245", "state": "upcoming", "primary_completion_date": "2027-08-15", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "224", "sponsor": "Biomed Industries, Inc.", "title": "Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese", "primary_outcome": "Change from baseline in body weight at 48 weeks", "record_url": "https://clinicaltrials.gov/study/NCT06732245" }, { "nct_id": "NCT07225686", "state": "upcoming", "primary_completion_date": "2027-08-20", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "250", "sponsor": "Amgen", "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy", "primary_outcome": "Change in Apnea-Hypopnea Index (AHI) from baseline at week 52", "record_url": "https://clinicaltrials.gov/study/NCT07225686" }, { "nct_id": "NCT07441252", "state": "upcoming", "primary_completion_date": "2027-08-25", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "180", "sponsor": "Amgen", "title": "A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight", "primary_outcome": "Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at Week 52", "record_url": "https://clinicaltrials.gov/study/NCT07441252" }, { "nct_id": "NCT07226765", "state": "upcoming", "primary_completion_date": "2027-08-30", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "250", "sponsor": "Amgen", "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy", "primary_outcome": "Change in Apnea-hypopnea Index (AHI) from baseline at Week 52", "record_url": "https://clinicaltrials.gov/study/NCT07226765" }, { "nct_id": "NCT07417306", "state": "upcoming", "primary_completion_date": "2027-08-30", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "912", "sponsor": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.", "title": "A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor", "primary_outcome": "Change from baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT07417306" }, { "nct_id": "NCT07301437", "state": "upcoming", "primary_completion_date": "2027-08-31", "primary_completion_type": "ESTIMATED", "drug": "liraglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "120", "sponsor": "The Fourth Affiliated Hospital of Zhejiang University School of Medicine", "title": "RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.", "primary_outcome": "weight loss", "record_url": "https://clinicaltrials.gov/study/NCT07301437" }, { "nct_id": "NCT05669755", "state": "upcoming", "primary_completion_date": "2027-09-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "7101", "sponsor": "Novo Nordisk A/S", "title": "REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels", "primary_outcome": "Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke", "record_url": "https://clinicaltrials.gov/study/NCT05669755" }, { "nct_id": "NCT06948435", "state": "upcoming", "primary_completion_date": "2027-09", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "487", "sponsor": "Eli Lilly and Company", "title": "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1", "primary_outcome": "Change from Baseline in office Systolic Blood Pressure (SBP)", "record_url": "https://clinicaltrials.gov/study/NCT06948435" }, { "nct_id": "NCT06952530", "state": "upcoming", "primary_completion_date": "2027-09", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "487", "sponsor": "Eli Lilly and Company", "title": "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2", "primary_outcome": "Change from Baseline in office Systolic Blood Pressure (SBP)", "record_url": "https://clinicaltrials.gov/study/NCT06952530" }, { "nct_id": "NCT06948422", "state": "upcoming", "primary_completion_date": "2027-09", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "974", "sponsor": "Eli Lilly and Company", "title": "A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)", "primary_outcome": "Number of Participants Allocated to Each ISA", "record_url": "https://clinicaltrials.gov/study/NCT06948422" }, { "nct_id": "NCT07136714", "state": "upcoming", "primary_completion_date": "2027-09", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "116", "sponsor": "Nordsjaellands Hospital", "title": "Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity", "primary_outcome": "Change in depressive symptoms", "record_url": "https://clinicaltrials.gov/study/NCT07136714" }, { "nct_id": "NCT07035093", "state": "upcoming", "primary_completion_date": "2027-09", "primary_completion_type": "ESTIMATED", "drug": "retatrutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "586", "sponsor": "Eli Lilly and Company", "title": "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain", "primary_outcome": "Change from Baseline in Pain Intensity Per Numeric Rating Scale", "record_url": "https://clinicaltrials.gov/study/NCT07035093" }, { "nct_id": "NCT06143956", "state": "upcoming", "primary_completion_date": "2027-09", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "RECRUITING", "enrollment": "1481", "sponsor": "Eli Lilly and Company", "title": "A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight", "primary_outcome": "Number of Participants Allocated to Each ISA", "record_url": "https://clinicaltrials.gov/study/NCT06143956" }, { "nct_id": "NCT07415954", "state": "upcoming", "primary_completion_date": "2027-09-03", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "270", "sponsor": "Novo Nordisk A/S", "title": "A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes", "primary_outcome": "Change in glycated haemoglobin (HbA1c) (week 16)", "record_url": "https://clinicaltrials.gov/study/NCT07415954" }, { "nct_id": "NCT03884075", "state": "upcoming", "primary_completion_date": "2027-09-03", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "104", "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "title": "Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)", "primary_outcome": "Histological Improvement", "record_url": "https://clinicaltrials.gov/study/NCT03884075" }, { "nct_id": "NCT07796477", "state": "upcoming", "primary_completion_date": "2027-09-28", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "240", "sponsor": "CSPC Ouyi Pharmaceutical Co., Ltd.", "title": "A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin", "primary_outcome": "Change from baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT07796477" }, { "nct_id": "NCT07009860", "state": "upcoming", "primary_completion_date": "2027-09-30", "primary_completion_type": "ESTIMATED", "drug": "pemvidutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "121", "sponsor": "Altimmune, Inc.", "title": "RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)", "primary_outcome": "Relative (%) reduction in liver stiffness by VCTE compared to baseline", "record_url": "https://clinicaltrials.gov/study/NCT07009860" }, { "nct_id": "NCT06651177", "state": "upcoming", "primary_completion_date": "2027-09-30", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "RECRUITING", "enrollment": "310", "sponsor": "T. John Winhusen, PhD", "title": "Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder", "primary_outcome": "6-month retention in BUP treatment", "record_url": "https://clinicaltrials.gov/study/NCT06651177" }, { "nct_id": "NCT07446998", "state": "upcoming", "primary_completion_date": "2027-10", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "239", "sponsor": "Veru Inc.", "title": "Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss", "primary_outcome": "To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.", "record_url": "https://clinicaltrials.gov/study/NCT07446998" }, { "nct_id": "NCT05556512", "state": "upcoming", "primary_completion_date": "2027-10", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "15374", "sponsor": "Eli Lilly and Company", "title": "A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity", "primary_outcome": "Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)", "record_url": "https://clinicaltrials.gov/study/NCT05556512" }, { "nct_id": "NCT06439277", "state": "upcoming", "primary_completion_date": "2027-10", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P3", "status": "RECRUITING", "enrollment": "300", "sponsor": "Eli Lilly and Company", "title": "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)", "primary_outcome": "Percent Change from Baseline in Body Mass Index (BMI)", "record_url": "https://clinicaltrials.gov/study/NCT06439277" }, { "nct_id": "NCT07628985", "state": "upcoming", "primary_completion_date": "2027-10", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "374", "sponsor": "Carnot Laboratories", "title": "BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes", "primary_outcome": "Change in Hemoglobin A1c (HbA1c) From Baseline at Week 30", "record_url": "https://clinicaltrials.gov/study/NCT07628985" }, { "nct_id": "NCT07668388", "state": "upcoming", "primary_completion_date": "2027-10-04", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "300", "sponsor": "Novo Nordisk A/S", "title": "A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes", "primary_outcome": "UBT251: Change in glycated haemoglobin (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT07668388" }, { "nct_id": "NCT07255209", "state": "upcoming", "primary_completion_date": "2027-10-31", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P3", "status": "RECRUITING", "enrollment": "180", "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "title": "A Study of IBI362 in Chinese Adolescents With Obesity or Overweight", "primary_outcome": "Percent Change from Baseline in BMI", "record_url": "https://clinicaltrials.gov/study/NCT07255209" }, { "nct_id": "NCT07697391", "state": "upcoming", "primary_completion_date": "2027-10-31", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "285", "sponsor": "The First Affiliated Hospital of Anhui Medical University", "title": "AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes", "primary_outcome": "Percent Change in Body Weight From Baseline to Week 52", "record_url": "https://clinicaltrials.gov/study/NCT07697391" }, { "nct_id": "NCT03811561", "state": "upcoming", "primary_completion_date": "2027-11-07", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "1500", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes", "primary_outcome": "Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.", "record_url": "https://clinicaltrials.gov/study/NCT03811561" }, { "nct_id": "NCT07589686", "state": "upcoming", "primary_completion_date": "2027-11-12", "primary_completion_type": "ESTIMATED", "drug": "petrelintide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "486", "sponsor": "Hoffmann-La Roche", "title": "A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight", "primary_outcome": "Percentage Change in Body Weight between Arms 1 and 6", "record_url": "https://clinicaltrials.gov/study/NCT07589686" }, { "nct_id": "NCT07206290", "state": "upcoming", "primary_completion_date": "2027-11-30", "primary_completion_type": "ESTIMATED", "drug": "survodutide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "120", "sponsor": "University Medical Center Groningen", "title": "Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease", "primary_outcome": "Change in first morning void UACR", "record_url": "https://clinicaltrials.gov/study/NCT07206290" }, { "nct_id": "NCT05702931", "state": "upcoming", "primary_completion_date": "2027-12", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "104", "sponsor": "Copenhagen University Hospital, Rigshospitalet", "title": "Semaglutide Treatment for Hyperglycaemia After Renal Transplantation", "primary_outcome": "Mean sensor glucose (mmol/L)", "record_url": "https://clinicaltrials.gov/study/NCT05702931" }, { "nct_id": "NCT07622810", "state": "upcoming", "primary_completion_date": "2027-12", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "352", "sponsor": "Carnot Laboratories", "title": "BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity", "primary_outcome": "Percent Change in Body Weight From Baseline to Week 36", "record_url": "https://clinicaltrials.gov/study/NCT07622810" }, { "nct_id": "NCT06847399", "state": "upcoming", "primary_completion_date": "2027-12-01", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "RECRUITING", "enrollment": "105", "sponsor": "Johns Hopkins University", "title": "Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder", "primary_outcome": "Percent initial weight loss", "record_url": "https://clinicaltrials.gov/study/NCT06847399" }, { "nct_id": "NCT06672939", "state": "upcoming", "primary_completion_date": "2027-12", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "RECRUITING", "enrollment": "150", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities", "primary_outcome": "Percent Change from Baseline in Body Mass Index (BMI)", "record_url": "https://clinicaltrials.gov/study/NCT06672939" }, { "nct_id": "NCT06814938", "state": "upcoming", "primary_completion_date": "2027-12", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "135", "sponsor": "Mayo Clinic", "title": "A Study of a Novel Precision Medicine Approach For Obesity", "primary_outcome": "Change in Total Body Weight at 24 weeks", "record_url": "https://clinicaltrials.gov/study/NCT06814938" }, { "nct_id": "NCT06499857", "state": "upcoming", "primary_completion_date": "2027-12", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "200", "sponsor": "University of Chicago", "title": "Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation", "primary_outcome": "Time to first AF event detected by routine outpatient monitoring", "record_url": "https://clinicaltrials.gov/study/NCT06499857" }, { "nct_id": "NCT06657209", "state": "upcoming", "primary_completion_date": "2027-12-15", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "RECRUITING", "enrollment": "104", "sponsor": "Stanford University", "title": "Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide", "primary_outcome": "Insulin resistance in normal weight women with diabetes compared to those with no diabetes", "record_url": "https://clinicaltrials.gov/study/NCT06657209" }, { "nct_id": "NCT07387094", "state": "upcoming", "primary_completion_date": "2027-12-16", "primary_completion_type": "ESTIMATED", "drug": "ecnoglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "140", "sponsor": "Hangzhou Sciwind Biosciences Co., Ltd.", "title": "A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy", "primary_outcome": "Change from baseline in Apnea-Hypopnea Index (AHI)", "record_url": "https://clinicaltrials.gov/study/NCT07387094" }, { "nct_id": "NCT07684144", "state": "upcoming", "primary_completion_date": "2027-12-26", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "950", "sponsor": "Amgen", "title": "Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)", "primary_outcome": "Percent Change in Body Weight from Baseline of the Parent Trial (20210184)", "record_url": "https://clinicaltrials.gov/study/NCT07684144" }, { "nct_id": "NCT07684235", "state": "upcoming", "primary_completion_date": "2027-12-26", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "3200", "sponsor": "Amgen", "title": "Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)", "primary_outcome": "Percent Change in Body Weight from Baseline of the Parent Trial (20210181)", "record_url": "https://clinicaltrials.gov/study/NCT07684235" }, { "nct_id": "NCT06423599", "state": "upcoming", "primary_completion_date": "2027-12-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2/P3", "status": "RECRUITING", "enrollment": "100", "sponsor": "Jens D Hove, MD,PHD", "title": "Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure", "primary_outcome": "Peak oxygen uptake", "record_url": "https://clinicaltrials.gov/study/NCT06423599" }, { "nct_id": "NCT07657676", "state": "upcoming", "primary_completion_date": "2027-12-31", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P4", "status": "RECRUITING", "enrollment": "116", "sponsor": "China National Center for Cardiovascular Diseases", "title": "Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity", "primary_outcome": "Change in total non-calcified plaque volume (NCPV) by CCTA from baseline to 52 weeks", "record_url": "https://clinicaltrials.gov/study/NCT07657676" }, { "nct_id": "NCT07244003", "state": "upcoming", "primary_completion_date": "2027-12-31", "primary_completion_type": "ESTIMATED", "drug": "liraglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "430", "sponsor": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.", "title": "Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control", "primary_outcome": "The change of HbA1c compared to the baseline", "record_url": "https://clinicaltrials.gov/study/NCT07244003" }, { "nct_id": "NCT07284511", "state": "upcoming", "primary_completion_date": "2028-01", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2/P3", "status": "RECRUITING", "enrollment": "105", "sponsor": "McGill University Health Centre/Research Institute of the McGill University Health Centre", "title": "A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar", "primary_outcome": "Daytime Time-in-Range", "record_url": "https://clinicaltrials.gov/study/NCT07284511" }, { "nct_id": "NCT07575399", "state": "upcoming", "primary_completion_date": "2028-01-03", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "300", "sponsor": "Amgen", "title": "Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)", "primary_outcome": "Percent Change from Baseline in Body Weight at Week 68", "record_url": "https://clinicaltrials.gov/study/NCT07575399" }, { "nct_id": "NCT07812597", "state": "upcoming", "primary_completion_date": "2028-01-13", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "210", "sponsor": "Beijing QL Biopharmaceutical Co.,Ltd", "title": "A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)", "primary_outcome": "Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomization", "record_url": "https://clinicaltrials.gov/study/NCT07812597" }, { "nct_id": "NCT07754461", "state": "upcoming", "primary_completion_date": "2028-01-17", "primary_completion_type": "ESTIMATED", "drug": "survodutide", "phase": "P3", "status": "RECRUITING", "enrollment": "600", "sponsor": "Boehringer Ingelheim", "title": "A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar", "primary_outcome": "Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41", "record_url": "https://clinicaltrials.gov/study/NCT07754461" }, { "nct_id": "NCT07685808", "state": "upcoming", "primary_completion_date": "2028-01-21", "primary_completion_type": "ESTIMATED", "drug": "olatorepatide", "phase": "P2", "status": "RECRUITING", "enrollment": "360", "sponsor": "Regeneron Pharmaceuticals", "title": "Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes", "primary_outcome": "Occurrence of Treatment-Emergent Adverse Events (TEAEs)", "record_url": "https://clinicaltrials.gov/study/NCT07685808" }, { "nct_id": "NCT07614412", "state": "upcoming", "primary_completion_date": "2028-01-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "240", "sponsor": "Ministry of Health, Saudi Arabia", "title": "SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.", "primary_outcome": "Change in 2-hour stimulated C-peptide Area Under the Curve (AUC) during a Mixed Meal Tolerance Test (MMTT)", "record_url": "https://clinicaltrials.gov/study/NCT07614412" }, { "nct_id": "NCT06788626", "state": "upcoming", "primary_completion_date": "2028-02", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "390", "sponsor": "Wei Hu", "title": "Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment", "primary_outcome": "The ordinal shift of modified Rankin Scale", "record_url": "https://clinicaltrials.gov/study/NCT06788626" }, { "nct_id": "NCT07213466", "state": "upcoming", "primary_completion_date": "2028-02-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "100", "sponsor": "Mayo Clinic", "title": "Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder", "primary_outcome": "Describe the distribution of obesity phenotypes (hungry brain, hungry gut, emotional hunger and slow burn) in patients with BD and obesity, with the goal of identifying predominant phenotype patterns within this clinical population.", "record_url": "https://clinicaltrials.gov/study/NCT07213466" }, { "nct_id": "NCT07112872", "state": "upcoming", "primary_completion_date": "2028-02-05", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "330", "sponsor": "Hoffmann-La Roche", "title": "A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes", "primary_outcome": "RO7795081 vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30", "record_url": "https://clinicaltrials.gov/study/NCT07112872" }, { "nct_id": "NCT07117240", "state": "upcoming", "primary_completion_date": "2028-02-09", "primary_completion_type": "ESTIMATED", "drug": "lixisenatide", "phase": "P4", "status": "ENROLLING_BY_INVITATION", "enrollment": "100", "sponsor": "Medical University of Warsaw", "title": "Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes", "primary_outcome": "Glucose monitoring index and Time in range", "record_url": "https://clinicaltrials.gov/study/NCT07117240" }, { "nct_id": "NCT07754045", "state": "upcoming", "primary_completion_date": "2028-02-15", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "202", "sponsor": "Lumos Pharma", "title": "Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults", "primary_outcome": "Proportion of participants with Short Physical Performance Battery (SPPB) score \u2264 7 at Week 26.", "record_url": "https://clinicaltrials.gov/study/NCT07754045" }, { "nct_id": "NCT07845500", "state": "upcoming", "primary_completion_date": "2028-02-16", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "660", "sponsor": "Pfizer", "title": "A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity", "primary_outcome": "Percent change from baseline in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07845500" }, { "nct_id": "NCT07770841", "state": "upcoming", "primary_completion_date": "2028-02-22", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "450", "sponsor": "Novo Nordisk A/S", "title": "Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight", "primary_outcome": "Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07770841" }, { "nct_id": "NCT07564414", "state": "upcoming", "primary_completion_date": "2028-02-23", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "2500", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight", "primary_outcome": "Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07564414" }, { "nct_id": "NCT07653477", "state": "upcoming", "primary_completion_date": "2028-02-29", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "956", "sponsor": "The United Bio-Technology (Hengqin) Co., Ltd.", "title": "Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin \u00b1 Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)", "primary_outcome": "HbA1c", "record_url": "https://clinicaltrials.gov/study/NCT07653477" }, { "nct_id": "NCT07676331", "state": "upcoming", "primary_completion_date": "2028-03-01", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "168", "sponsor": "Universitaire Ziekenhuizen KU Leuven", "title": "Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial", "primary_outcome": "Ki67 proliferation marker", "record_url": "https://clinicaltrials.gov/study/NCT07676331" }, { "nct_id": "NCT07790861", "state": "upcoming", "primary_completion_date": "2028-03", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "192", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems", "primary_outcome": "Mean Percent Change From Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT07790861" }, { "nct_id": "NCT07284979", "state": "upcoming", "primary_completion_date": "2028-03", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "1270", "sponsor": "Kailera", "title": "Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes", "primary_outcome": "Percent Change From Baseline in Body Weight at Week 76", "record_url": "https://clinicaltrials.gov/study/NCT07284979" }, { "nct_id": "NCT07602699", "state": "upcoming", "primary_completion_date": "2028-03", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "RECRUITING", "enrollment": "300", "sponsor": "University of Southern California", "title": "Multi-Site Trial of Tirzepatide for Smoking Cessation", "primary_outcome": "7-day point prevalence abstinence", "record_url": "https://clinicaltrials.gov/study/NCT07602699" }, { "nct_id": "NCT07202884", "state": "upcoming", "primary_completion_date": "2028-03", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "RECRUITING", "enrollment": "1000", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight", "primary_outcome": "Change from Baseline in Incontinence Episode Frequency (IEF)", "record_url": "https://clinicaltrials.gov/study/NCT07202884" }, { "nct_id": "NCT07468552", "state": "upcoming", "primary_completion_date": "2028-03-15", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "100", "sponsor": "National Institute on Drug Abuse (NIDA)", "title": "Trial of Tirzepatide for the Treatment of Cannabis Use Disorder", "primary_outcome": "Maximum Tolerated Dose (MTD)", "record_url": "https://clinicaltrials.gov/study/NCT07468552" }, { "nct_id": "NCT07859176", "state": "upcoming", "primary_completion_date": "2028-04", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "100", "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt", "title": "Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery", "primary_outcome": "Percentage change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07859176" }, { "nct_id": "NCT06859268", "state": "upcoming", "primary_completion_date": "2028-04", "primary_completion_type": "ESTIMATED", "drug": "retatrutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "643", "sponsor": "Eli Lilly and Company", "title": "A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity", "primary_outcome": "Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT06859268" }, { "nct_id": "NCT07153471", "state": "upcoming", "primary_completion_date": "2028-04", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "800", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee", "primary_outcome": "Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score", "record_url": "https://clinicaltrials.gov/study/NCT07153471" }, { "nct_id": "NCT06937086", "state": "upcoming", "primary_completion_date": "2028-04", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P3", "status": "RECRUITING", "enrollment": "350", "sponsor": "Eli Lilly and Company", "title": "Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study", "primary_outcome": "Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction", "record_url": "https://clinicaltrials.gov/study/NCT06937086" }, { "nct_id": "NCT07523633", "state": "upcoming", "primary_completion_date": "2028-04-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "100", "sponsor": "Anders Fink-Jensen, MD, DMSci", "title": "Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder", "primary_outcome": "Cannabis consumption", "record_url": "https://clinicaltrials.gov/study/NCT07523633" }, { "nct_id": "NCT06937099", "state": "upcoming", "primary_completion_date": "2028-05", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P3", "status": "RECRUITING", "enrollment": "290", "sponsor": "Eli Lilly and Company", "title": "Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight", "primary_outcome": "Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction", "record_url": "https://clinicaltrials.gov/study/NCT06937099" }, { "nct_id": "NCT06857942", "state": "upcoming", "primary_completion_date": "2028-05", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "RECRUITING", "enrollment": "200", "sponsor": "Eli Lilly and Company", "title": "A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)", "primary_outcome": "Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1)", "record_url": "https://clinicaltrials.gov/study/NCT06857942" }, { "nct_id": "NCT07662213", "state": "upcoming", "primary_completion_date": "2028-05-23", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "1200", "sponsor": "AstraZeneca", "title": "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus", "primary_outcome": "Change from baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT07662213" }, { "nct_id": "NCT06173778", "state": "upcoming", "primary_completion_date": "2028-05-25", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "197", "sponsor": "The University of Texas Health Science Center, Houston", "title": "Semaglutide for Post-Smoking Cessation Weight Management", "primary_outcome": "Change in Body Weight Percent", "record_url": "https://clinicaltrials.gov/study/NCT06173778" }, { "nct_id": "NCT07734792", "state": "upcoming", "primary_completion_date": "2028-05-31", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2/P3", "status": "NOT_YET_RECRUITING", "enrollment": "726", "sponsor": "yifang zhu", "title": "Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial", "primary_outcome": "The primary efficacy outcome: Proportion of patients achieving an excellent functional outcome", "record_url": "https://clinicaltrials.gov/study/NCT07734792" }, { "nct_id": "NCT07734311", "state": "upcoming", "primary_completion_date": "2028-05-31", "primary_completion_type": "ESTIMATED", "drug": "ecnoglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "360", "sponsor": "Hangzhou Sciwind Biosciences Co., Ltd.", "title": "A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)", "primary_outcome": "Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score", "record_url": "https://clinicaltrials.gov/study/NCT07734311" }, { "nct_id": "NCT07755085", "state": "upcoming", "primary_completion_date": "2028-06-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "100", "sponsor": "Nova Scotia Health Authority", "title": "GLP-1s in Hip and Knee Arthroplasty", "primary_outcome": "Incidence of Wound Complication after Joint Arthroplasty", "record_url": "https://clinicaltrials.gov/study/NCT07755085" }, { "nct_id": "NCT07239570", "state": "upcoming", "primary_completion_date": "2028-06", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "125", "sponsor": "Peter Rossing", "title": "A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease", "primary_outcome": "Chronic eGFR slope", "record_url": "https://clinicaltrials.gov/study/NCT07239570" }, { "nct_id": "NCT06909006", "state": "upcoming", "primary_completion_date": "2028-06", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "122", "sponsor": "Nordsjaellands Hospital", "title": "Semaglutide Treatment in Type 1 Diabetes", "primary_outcome": "Body weight", "record_url": "https://clinicaltrials.gov/study/NCT06909006" }, { "nct_id": "NCT07223593", "state": "upcoming", "primary_completion_date": "2028-06", "primary_completion_type": "ESTIMATED", "drug": "orforglipron", "phase": "P3", "status": "RECRUITING", "enrollment": "1205", "sponsor": "Eli Lilly and Company", "title": "Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease", "primary_outcome": "Percent Change from Baseline in Maximum Walking Distance", "record_url": "https://clinicaltrials.gov/study/NCT07223593" }, { "nct_id": "NCT07654062", "state": "upcoming", "primary_completion_date": "2028-06", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "150", "sponsor": "Shandong Provincial Hospital", "title": "Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)", "primary_outcome": "Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 24", "record_url": "https://clinicaltrials.gov/study/NCT07654062" }, { "nct_id": "NCT07836270", "state": "upcoming", "primary_completion_date": "2028-06-08", "primary_completion_type": "ESTIMATED", "drug": "ecnoglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "192", "sponsor": "Hangzhou Sciwind Biosciences Co., Ltd.", "title": "A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents", "primary_outcome": "Percent change in Body Mass Index (BMI)", "record_url": "https://clinicaltrials.gov/study/NCT07836270" }, { "nct_id": "NCT07613437", "state": "upcoming", "primary_completion_date": "2028-06-14", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "200", "sponsor": "Chinese University of Hong Kong", "title": "GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial", "primary_outcome": "Edema extension distance on Day 7", "record_url": "https://clinicaltrials.gov/study/NCT07613437" }, { "nct_id": "NCT07434050", "state": "upcoming", "primary_completion_date": "2028-06-19", "primary_completion_type": "ESTIMATED", "drug": "ecnoglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "140", "sponsor": "Hangzhou Sciwind Biosciences Co., Ltd.", "title": "A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy", "primary_outcome": "Change from baseline in Apnea-Hypopnea Index (AHI)", "record_url": "https://clinicaltrials.gov/study/NCT07434050" }, { "nct_id": "NCT07855900", "state": "upcoming", "primary_completion_date": "2028-06-25", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "350", "sponsor": "Boehringer Ingelheim", "title": "SYNCHRONIZE\u00ae-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight", "primary_outcome": "Percent change in body weight from baseline to Week 52", "record_url": "https://clinicaltrials.gov/study/NCT07855900" }, { "nct_id": "NCT07037433", "state": "upcoming", "primary_completion_date": "2028-06-30", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "12800", "sponsor": "Amgen", "title": "Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity", "primary_outcome": "Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE])", "record_url": "https://clinicaltrials.gov/study/NCT07037433" }, { "nct_id": "NCT07037459", "state": "upcoming", "primary_completion_date": "2028-06-30", "primary_completion_type": "ESTIMATED", "drug": "maridebart cafraglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "5056", "sponsor": "Amgen", "title": "Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity", "primary_outcome": "Time to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF Events", "record_url": "https://clinicaltrials.gov/study/NCT07037459" }, { "nct_id": "NCT06132477", "state": "upcoming", "primary_completion_date": "2028-07", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "150", "sponsor": "University of Missouri-Columbia", "title": "Impact GLP-1 Agonists Following Bariatric", "primary_outcome": "Effect of GLP1-RA on weight loss", "record_url": "https://clinicaltrials.gov/study/NCT06132477" }, { "nct_id": "NCT07868835", "state": "upcoming", "primary_completion_date": "2028-07", "primary_completion_type": "ESTIMATED", "drug": "VK2735", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "560", "sponsor": "Viking Therapeutics, Inc.", "title": "Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)", "primary_outcome": "Percentage change in body weight for participants receiving VK2735 orally once daily", "record_url": "https://clinicaltrials.gov/study/NCT07868835" }, { "nct_id": "NCT07850050", "state": "upcoming", "primary_completion_date": "2028-07-26", "primary_completion_type": "ESTIMATED", "drug": "survodutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "600", "sponsor": "Boehringer Ingelheim", "title": "SYNCHRONIZE\u00ae-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight", "primary_outcome": "Percentage change in body weight from baseline to Week 52", "record_url": "https://clinicaltrials.gov/study/NCT07850050" }, { "nct_id": "NCT06939088", "state": "upcoming", "primary_completion_date": "2028-08-01", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2", "status": "RECRUITING", "enrollment": "108", "sponsor": "Anders Fink-Jensen, MD, DMSci", "title": "Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder", "primary_outcome": "Change in heavy drinking days", "record_url": "https://clinicaltrials.gov/study/NCT06939088" }, { "nct_id": "NCT06792422", "state": "upcoming", "primary_completion_date": "2028-08", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "126", "sponsor": "Glostrup University Hospital, Copenhagen", "title": "A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma", "primary_outcome": "Photopic negative response of the electroretinogram after 6 months", "record_url": "https://clinicaltrials.gov/study/NCT06792422" }, { "nct_id": "NCT07046273", "state": "upcoming", "primary_completion_date": "2028-08-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "496", "sponsor": "Shandong New Time Pharmaceutical Co., LTD", "title": "Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic\u00ae in Patients With Type 2 Diabetes", "primary_outcome": "Change in HbA1c from baseline", "record_url": "https://clinicaltrials.gov/study/NCT07046273" }, { "nct_id": "NCT05441267", "state": "upcoming", "primary_completion_date": "2028-08-17", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "21296", "sponsor": "University of Oxford", "title": "A Study of Cardiovascular Events iN Diabetes Plus", "primary_outcome": "Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+)", "record_url": "https://clinicaltrials.gov/study/NCT05441267" }, { "nct_id": "NCT06780449", "state": "upcoming", "primary_completion_date": "2028-08-28", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "400", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity", "primary_outcome": "Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT06780449" }, { "nct_id": "NCT07617155", "state": "upcoming", "primary_completion_date": "2028-09", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "396", "sponsor": "Peking Union Medical College Hospital", "title": "GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis", "primary_outcome": "Proportion of participants with recurrent hypertriglyceridemia-induced acute pancreatitis", "record_url": "https://clinicaltrials.gov/study/NCT07617155" }, { "nct_id": "NCT07654374", "state": "upcoming", "primary_completion_date": "2028-09", "primary_completion_type": "ESTIMATED", "drug": "aleniglipron", "phase": "P3", "status": "RECRUITING", "enrollment": "1100", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "title": "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)", "primary_outcome": "Percent change in body weight from Baseline", "record_url": "https://clinicaltrials.gov/study/NCT07654374" }, { "nct_id": "NCT07654361", "state": "upcoming", "primary_completion_date": "2028-09", "primary_completion_type": "ESTIMATED", "drug": "aleniglipron", "phase": "P3", "status": "RECRUITING", "enrollment": "3600", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "title": "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)", "primary_outcome": "Percent change in body weight from Baseline", "record_url": "https://clinicaltrials.gov/study/NCT07654361" }, { "nct_id": "NCT07866066", "state": "upcoming", "primary_completion_date": "2028-09-04", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "1300", "sponsor": "Amgen", "title": "Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority]", "record_url": "https://clinicaltrials.gov/study/NCT07866066" }, { "nct_id": "NCT07555730", "state": "upcoming", "primary_completion_date": "2028-09-30", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "400", "sponsor": "Huazhong University of Science and Technology", "title": "AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)", "primary_outcome": "Body weight change (kg)", "record_url": "https://clinicaltrials.gov/study/NCT07555730" }, { "nct_id": "NCT07743983", "state": "upcoming", "primary_completion_date": "2028-09-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "372", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "title": "A Study of BGM0504 in Early T2DM With Obesity", "primary_outcome": "Proportion of Participants Achieving HbA1c < 7.0% and Body Weight Reduction \u2265 10% from Baseline", "record_url": "https://clinicaltrials.gov/study/NCT07743983" }, { "nct_id": "NCT07859189", "state": "upcoming", "primary_completion_date": "2028-10", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "100", "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt", "title": "Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery", "primary_outcome": "Percentage total weight loss", "record_url": "https://clinicaltrials.gov/study/NCT07859189" }, { "nct_id": "NCT07357415", "state": "upcoming", "primary_completion_date": "2028-10", "primary_completion_type": "ESTIMATED", "drug": "retatrutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "600", "sponsor": "Eli Lilly and Company", "title": "A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight", "primary_outcome": "Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT07357415" }, { "nct_id": "NCT07868939", "state": "upcoming", "primary_completion_date": "2028-10", "primary_completion_type": "ESTIMATED", "drug": "VK2735", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "560", "sponsor": "Viking Therapeutics, Inc.", "title": "Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)", "primary_outcome": "Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily", "record_url": "https://clinicaltrials.gov/study/NCT07868939" }, { "nct_id": "NCT07668414", "state": "upcoming", "primary_completion_date": "2028-10-10", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "650", "sponsor": "Novo Nordisk A/S", "title": "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide", "primary_outcome": "Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07668414" }, { "nct_id": "NCT07843485", "state": "upcoming", "primary_completion_date": "2028-10-20", "primary_completion_type": "ESTIMATED", "drug": "petrelintide", "phase": "P3", "status": "RECRUITING", "enrollment": "600", "sponsor": "Hoffmann-La Roche", "title": "A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes", "primary_outcome": "Percentage Change in Body Weight from Baseline", "record_url": "https://clinicaltrials.gov/study/NCT07843485" }, { "nct_id": "NCT07511543", "state": "upcoming", "primary_completion_date": "2028-10-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "100", "sponsor": "Population Health Research Institute", "title": "Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy", "primary_outcome": "Feasibility - Recruitment", "record_url": "https://clinicaltrials.gov/study/NCT07511543" }, { "nct_id": "NCT07859137", "state": "upcoming", "primary_completion_date": "2028-11", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "100", "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt", "title": "Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m\u00b2 or Higher", "primary_outcome": "Mean operative difficulty score", "record_url": "https://clinicaltrials.gov/study/NCT07859137" }, { "nct_id": "NCT06571383", "state": "upcoming", "primary_completion_date": "2028-11-15", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "500", "sponsor": "Novo Nordisk A/S", "title": "STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss", "primary_outcome": "Maintenance of Body Mass Index (BMI) below obesity threshold", "record_url": "https://clinicaltrials.gov/study/NCT06571383" }, { "nct_id": "NCT07830329", "state": "upcoming", "primary_completion_date": "2028-11-24", "primary_completion_type": "ESTIMATED", "drug": "olatorepatide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "300", "sponsor": "Regeneron Pharmaceuticals", "title": "Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity", "primary_outcome": "Percent change in total Abscess and inflammatory Nodule (AN) count", "record_url": "https://clinicaltrials.gov/study/NCT07830329" }, { "nct_id": "NCT07592546", "state": "upcoming", "primary_completion_date": "2028-12-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "240", "sponsor": "Alain Dagher", "title": "Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss", "primary_outcome": "Serum C-reactive Protein (CRP)", "record_url": "https://clinicaltrials.gov/study/NCT07592546" }, { "nct_id": "NCT07795164", "state": "upcoming", "primary_completion_date": "2028-12", "primary_completion_type": "ESTIMATED", "drug": "pemvidutide", "phase": "P3", "status": "RECRUITING", "enrollment": "1800", "sponsor": "Altimmune, Inc.", "title": "Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH", "primary_outcome": "Clinical Outcome Event", "record_url": "https://clinicaltrials.gov/study/NCT07795164" }, { "nct_id": "NCT07326111", "state": "upcoming", "primary_completion_date": "2028-12", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "RECRUITING", "enrollment": "198", "sponsor": "University of Bonn", "title": "A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese", "primary_outcome": "Improvement of ovarian dysfunction as defined by menstrual irregularity in overweight or obesity-related PCOS", "record_url": "https://clinicaltrials.gov/study/NCT07326111" }, { "nct_id": "NCT07846865", "state": "upcoming", "primary_completion_date": "2028-12-01", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P2/P3", "status": "NOT_YET_RECRUITING", "enrollment": "256", "sponsor": "Woolcock Institute of Medical Research", "title": "Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial", "primary_outcome": "Breathing Disturbance Index (BDI)", "record_url": "https://clinicaltrials.gov/study/NCT07846865" }, { "nct_id": "NCT07400107", "state": "upcoming", "primary_completion_date": "2028-12-12", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "1000", "sponsor": "Novo Nordisk A/S", "title": "AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight", "primary_outcome": "Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07400107" }, { "nct_id": "NCT07843498", "state": "upcoming", "primary_completion_date": "2028-12-21", "primary_completion_type": "ESTIMATED", "drug": "petrelintide", "phase": "P3", "status": "RECRUITING", "enrollment": "3900", "sponsor": "Hoffmann-La Roche", "title": "A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity", "primary_outcome": "Percentage Change in Body Weight from Baseline", "record_url": "https://clinicaltrials.gov/study/NCT07843498" }, { "nct_id": "NCT07275697", "state": "upcoming", "primary_completion_date": "2028-12-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "200", "sponsor": "Emma Svennberg", "title": "Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study", "primary_outcome": "Arrhythmia-free survival at 12 months after catheter ablation, excluding the 3-month blanking period, with recurrence defined as any ILR-detected AF, atrial flutter, or atrial tachycardia \u226530 seconds.", "record_url": "https://clinicaltrials.gov/study/NCT07275697" }, { "nct_id": "NCT06946628", "state": "upcoming", "primary_completion_date": "2028-12-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "296", "sponsor": "Sun Yat-sen University", "title": "New Triple Therapy in Newly Diagnosed Type 2 Diabetes", "primary_outcome": "Diabetic remission rate", "record_url": "https://clinicaltrials.gov/study/NCT06946628" }, { "nct_id": "NCT06324461", "state": "upcoming", "primary_completion_date": "2028-12-31", "primary_completion_type": "ESTIMATED", "drug": "dulaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "372", "sponsor": "The University of Hong Kong", "title": "GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery", "primary_outcome": "Proportion of patients with MINS", "record_url": "https://clinicaltrials.gov/study/NCT06324461" }, { "nct_id": "NCT07858331", "state": "upcoming", "primary_completion_date": "2029-01-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "880", "sponsor": "Kristin Clemens", "title": "Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access", "primary_outcome": "Change in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT07858331" }, { "nct_id": "NCT05700877", "state": "upcoming", "primary_completion_date": "2029-01-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "7300", "sponsor": "Per L\u00f8gstrup Poulsen", "title": "Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes", "primary_outcome": "Rates of a composite cardiovascular endpoint", "record_url": "https://clinicaltrials.gov/study/NCT05700877" }, { "nct_id": "NCT06383390", "state": "upcoming", "primary_completion_date": "2029-02", "primary_completion_type": "ESTIMATED", "drug": "retatrutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "10000", "sponsor": "Eli Lilly and Company", "title": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)", "primary_outcome": "Time to First Occurrence of Composite Endpoints", "record_url": "https://clinicaltrials.gov/study/NCT06383390" }, { "nct_id": "NCT07775846", "state": "upcoming", "primary_completion_date": "2029-02-28", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "820", "sponsor": "Huijie Zhang", "title": "QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy", "primary_outcome": "Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6", "record_url": "https://clinicaltrials.gov/study/NCT07775846" }, { "nct_id": "NCT05390892", "state": "upcoming", "primary_completion_date": "2029-03-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "6000", "sponsor": "Brigham and Women's Hospital", "title": "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes", "primary_outcome": "Total (first and recurrent) cardiovascular, kidney, and death events", "record_url": "https://clinicaltrials.gov/study/NCT05390892" }, { "nct_id": "NCT07218354", "state": "upcoming", "primary_completion_date": "2029-03-31", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "622", "sponsor": "VA Office of Research and Development", "title": "Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)", "primary_outcome": "Two-level reduction in the World Health Organization (WHO) risk drinking level assessed in the last 28 days of intervention", "record_url": "https://clinicaltrials.gov/study/NCT07218354" }, { "nct_id": "NCT07389941", "state": "upcoming", "primary_completion_date": "2029-04", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "240", "sponsor": "University of Luebeck", "title": "Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation", "primary_outcome": "Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period)", "record_url": "https://clinicaltrials.gov/study/NCT07389941" }, { "nct_id": "NCT07859163", "state": "upcoming", "primary_completion_date": "2029-04", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "100", "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt", "title": "Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain", "primary_outcome": "Percentage total weight loss", "record_url": "https://clinicaltrials.gov/study/NCT07859163" }, { "nct_id": "NCT07859150", "state": "upcoming", "primary_completion_date": "2029-04", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "NOT_YET_RECRUITING", "enrollment": "104", "sponsor": "General Committee of Teaching Hospitals and Institutes, Egypt", "title": "Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)", "primary_outcome": "Mean percentage change in body weight from randomization", "record_url": "https://clinicaltrials.gov/study/NCT07859150" }, { "nct_id": "NCT07505303", "state": "overdue", "primary_completion_date": "2026-10-15", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "151", "sponsor": "Eccogene", "title": "MIST (Metabolic Intervention With Semaglutide and THR-\u03b2 Therapy) Trial", "primary_outcome": "Percentage Change in Body Weight from Baseline (Week 9) to Week 20", "record_url": "https://clinicaltrials.gov/study/NCT07505303" }, { "nct_id": "NCT06257966", "state": "overdue", "primary_completion_date": "2026-10-01", "primary_completion_type": "ESTIMATED", "drug": "dulaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "600", "sponsor": "Beijing Dongfang Biotech Co., Ltd.", "title": "A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin", "primary_outcome": "HbA1c", "record_url": "https://clinicaltrials.gov/study/NCT06257966" }, { "nct_id": "NCT05254314", "state": "reached", "primary_completion_date": "2026-09-28", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "100", "sponsor": "Vanderbilt University Medical Center", "title": "Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)", "primary_outcome": "The efficacy of semaglutide on asthma control questionnaire-7 score in subjects with symptoms, persistent asthma and obesity.", "record_url": "https://clinicaltrials.gov/study/NCT05254314" }, { "nct_id": "NCT06862908", "state": "overdue", "primary_completion_date": "2026-09-24", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "141", "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "title": "A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity", "primary_outcome": "Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)", "record_url": "https://clinicaltrials.gov/study/NCT06862908" }, { "nct_id": "NCT06671587", "state": "overdue", "primary_completion_date": "2026-09-18", "primary_completion_type": "ESTIMATED", "drug": "lixisenatide", "phase": "P4", "status": "RECRUITING", "enrollment": "678", "sponsor": "Sanofi", "title": "iGlarLixi CGM Study in Chinese T2D Individuals After OADs", "primary_outcome": "Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)]", "record_url": "https://clinicaltrials.gov/study/NCT06671587" }, { "nct_id": "NCT06965413", "state": "reached", "primary_completion_date": "2026-09-03", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "285", "sponsor": "Hoffmann-La Roche", "title": "A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity", "primary_outcome": "Percent Change From Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT06965413" }, { "nct_id": "NCT06717698", "state": "overdue", "primary_completion_date": "2026-09-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "465", "sponsor": "Novo Nordisk A/S", "title": "A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease", "primary_outcome": "Change in urinary albumin-to-creatinine ratio (UACR) at week 12", "record_url": "https://clinicaltrials.gov/study/NCT06717698" }, { "nct_id": "NCT07225829", "state": "reached", "primary_completion_date": "2026-08-31", "primary_completion_type": "ACTUAL", "drug": "liraglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "129", "sponsor": "4Moving Biotech", "title": "A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis", "primary_outcome": "Change from Baseline at Week 4 in the weekly average of Target Knee (TK) daily pain intensity using the WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain subscore", "record_url": "https://clinicaltrials.gov/study/NCT07225829" }, { "nct_id": "NCT06260722", "state": "reached", "primary_completion_date": "2026-08-27", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "1250", "sponsor": "Eli Lilly and Company", "title": "Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c) (%)", "record_url": "https://clinicaltrials.gov/study/NCT06260722" }, { "nct_id": "NCT06926842", "state": "reached", "primary_completion_date": "2026-08-13", "primary_completion_type": "ACTUAL", "drug": "petrelintide", "phase": "P2", "status": "COMPLETED", "enrollment": "221", "sponsor": "Zealand Pharma", "title": "Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)", "primary_outcome": "Percentage Change in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT06926842" }, { "nct_id": "NCT07179120", "state": "overdue", "primary_completion_date": "2026-08-12", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "NOT_YET_RECRUITING", "enrollment": "180", "sponsor": "First Affiliated Hospital of Wenzhou Medical University", "title": "Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health", "primary_outcome": "Change from Baseline in Sperm Concentration (million/mL) at Week 32 of Intervention", "record_url": "https://clinicaltrials.gov/study/NCT07179120" }, { "nct_id": "NCT07469800", "state": "overdue", "primary_completion_date": "2026-08-01", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P3", "status": "RECRUITING", "enrollment": "336", "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "title": "Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity", "primary_outcome": "To evaluate the effect of IBI362 on mean sitting systolic blood pressure (msSBP) compared with placebo at Week 16 of treatment.", "record_url": "https://clinicaltrials.gov/study/NCT07469800" }, { "nct_id": "NCT06987513", "state": "reached", "primary_completion_date": "2026-07-30", "primary_completion_type": "ACTUAL", "drug": "pemvidutide", "phase": "P2", "status": "COMPLETED", "enrollment": "100", "sponsor": "Altimmune, Inc.", "title": "RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight", "primary_outcome": "Change from baseline in the average number of heavy drinking days per week", "record_url": "https://clinicaltrials.gov/study/NCT06987513" }, { "nct_id": "NCT07281937", "state": "reached", "primary_completion_date": "2026-07-23", "primary_completion_type": "ACTUAL", "drug": "ecnoglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "206", "sponsor": "Verdiva Bio Dev Limited", "title": "A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "primary_outcome": "Mean percent change from baseline in body weight", "record_url": "https://clinicaltrials.gov/study/NCT07281937" }, { "nct_id": "NCT06649045", "state": "reached", "primary_completion_date": "2026-07-21", "primary_completion_type": "ACTUAL", "drug": "orforglipron", "phase": "P3", "status": "COMPLETED", "enrollment": "712", "sponsor": "Eli Lilly and Company", "title": "A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight", "primary_outcome": "Change from Baseline in Apnea-Hypopnea Index (AHI)", "record_url": "https://clinicaltrials.gov/study/NCT06649045" }, { "nct_id": "NCT06649344", "state": "reached", "primary_completion_date": "2026-07-18", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "884", "sponsor": "Fujian Shengdi Pharmaceutical Co., Ltd.", "title": "A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes", "primary_outcome": "Change in HbA1c", "record_url": "https://clinicaltrials.gov/study/NCT06649344" }, { "nct_id": "NCT05536804", "state": "reached", "primary_completion_date": "2026-07-06", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P2", "status": "COMPLETED", "enrollment": "134", "sponsor": "Eli Lilly and Company", "title": "A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "primary_outcome": "Percent Change from Baseline in Renal Sinus Fat Content (MRI)", "record_url": "https://clinicaltrials.gov/study/NCT05536804" }, { "nct_id": "NCT06603571", "state": "reached", "primary_completion_date": "2026-07-01", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P2", "status": "COMPLETED", "enrollment": "367", "sponsor": "Eli Lilly and Company", "title": "A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes", "primary_outcome": "Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT06603571" }, { "nct_id": "NCT06918405", "state": "overdue", "primary_completion_date": "2026-06-30", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "440", "sponsor": "Chittagong Medical College", "title": "Efficacy and Safety of Tirzepatide for Weight Management", "primary_outcome": "Change in body weight (kg)", "record_url": "https://clinicaltrials.gov/study/NCT06918405" }, { "nct_id": "NCT07272343", "state": "overdue", "primary_completion_date": "2026-06-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "100", "sponsor": "Second Affiliated Hospital of Nanchang University", "title": "The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes", "primary_outcome": "HbA1c", "record_url": "https://clinicaltrials.gov/study/NCT07272343" }, { "nct_id": "NCT04873245", "state": "reached", "primary_completion_date": "2026-06-29", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "120", "sponsor": "University of Minnesota", "title": "Lifestyle Counseling and Medication for Adolescent Weight Management", "primary_outcome": "Change in body mass index", "record_url": "https://clinicaltrials.gov/study/NCT04873245" }, { "nct_id": "NCT07271251", "state": "reached", "primary_completion_date": "2026-06-29", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "267", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes", "primary_outcome": "Change in glycated haemoglobin (HbA1c).", "record_url": "https://clinicaltrials.gov/study/NCT07271251" }, { "nct_id": "NCT06797869", "state": "reached", "primary_completion_date": "2026-06-26", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "142", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy", "primary_outcome": "Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)", "record_url": "https://clinicaltrials.gov/study/NCT06797869" }, { "nct_id": "NCT06299098", "state": "reached", "primary_completion_date": "2026-06-16", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "1005", "sponsor": "Regeneron Pharmaceuticals", "title": "A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation", "primary_outcome": "Incidence of treatment-emergent adverse events (TEAEs)", "record_url": "https://clinicaltrials.gov/study/NCT06299098" }, { "nct_id": "NCT05929079", "state": "reached", "primary_completion_date": "2026-06-16", "primary_completion_type": "ACTUAL", "drug": "retatrutide", "phase": "P3", "status": "COMPLETED", "enrollment": "1152", "sponsor": "Eli Lilly and Company", "title": "A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight", "primary_outcome": "Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT05929079" }, { "nct_id": "NCT06716424", "state": "reached", "primary_completion_date": "2026-06-12", "primary_completion_type": "ACTUAL", "drug": "lixisenatide", "phase": "P4", "status": "COMPLETED", "enrollment": "105", "sponsor": "Sanofi", "title": "A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus", "primary_outcome": "Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs)", "record_url": "https://clinicaltrials.gov/study/NCT06716424" }, { "nct_id": "NCT06534411", "state": "reached", "primary_completion_date": "2026-06-02", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "1023", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both", "primary_outcome": "Change in Glycated Haemoglobin (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06534411" }, { "nct_id": "NCT06075667", "state": "reached", "primary_completion_date": "2026-06-02", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "160", "sponsor": "Eli Lilly and Company", "title": "A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "primary_outcome": "Percent Change from Baseline in Body Mass Index (BMI)", "record_url": "https://clinicaltrials.gov/study/NCT06075667" }, { "nct_id": "NCT06077864", "state": "reached", "primary_completion_date": "2026-06-01", "primary_completion_type": "ACTUAL", "drug": "survodutide", "phase": "P3", "status": "COMPLETED", "enrollment": "5531", "sponsor": "Boehringer Ingelheim", "title": "A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE\u2122 - CVOT)", "primary_outcome": "Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, non-fatal MI, ischaemia related coronary revascularisation, or HFE (to demonstrate non-inferiority)", "record_url": "https://clinicaltrials.gov/study/NCT06077864" }, { "nct_id": "NCT06633783", "state": "overdue", "primary_completion_date": "2026-05-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "NOT_YET_RECRUITING", "enrollment": "370", "sponsor": "Hangzhou Jiuyuan Gene Engineering Co. Ltd.,", "title": "A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy\u00ae", "primary_outcome": "Change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT06633783" }, { "nct_id": "NCT06254014", "state": "overdue", "primary_completion_date": "2026-05-01", "primary_completion_type": "ESTIMATED", "drug": "exenatide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "270", "sponsor": "Beijing Dongfang Biotech Co., Ltd.", "title": "A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients", "primary_outcome": "HbA1c", "record_url": "https://clinicaltrials.gov/study/NCT06254014" }, { "nct_id": "NCT06937749", "state": "overdue", "primary_completion_date": "2026-04-30", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P2", "status": "RECRUITING", "enrollment": "165", "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "title": "A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)", "primary_outcome": "Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology", "record_url": "https://clinicaltrials.gov/study/NCT06937749" }, { "nct_id": "NCT07610174", "state": "reached", "primary_completion_date": "2026-04-29", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "160", "sponsor": "Kafrelsheikh University", "title": "Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves", "primary_outcome": "Change from Baseline in Left Ventricular Global Longitudinal Strain (LV-GLS) assessed by echocardiography", "record_url": "https://clinicaltrials.gov/study/NCT07610174" }, { "nct_id": "NCT06388187", "state": "reached", "primary_completion_date": "2026-04-22", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "300", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight", "primary_outcome": "Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT06388187" }, { "nct_id": "NCT05882045", "state": "reached", "primary_completion_date": "2026-04-16", "primary_completion_type": "ACTUAL", "drug": "retatrutide", "phase": "P3", "status": "COMPLETED", "enrollment": "1946", "sponsor": "Eli Lilly and Company", "title": "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease", "primary_outcome": "Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT05882045" }, { "nct_id": "NCT06635057", "state": "reached", "primary_completion_date": "2026-04-15", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P4", "status": "COMPLETED", "enrollment": "166", "sponsor": "Eli Lilly and Company", "title": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06635057" }, { "nct_id": "NCT07834398", "state": "reached", "primary_completion_date": "2026-04-13", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "150", "sponsor": "Zagazig University", "title": "Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes", "primary_outcome": "change in body weight at 3 and 6 months", "record_url": "https://clinicaltrials.gov/study/NCT07834398" }, { "nct_id": "NCT05929066", "state": "reached", "primary_completion_date": "2026-04-06", "primary_completion_type": "ACTUAL", "drug": "retatrutide", "phase": "P3", "status": "COMPLETED", "enrollment": "2335", "sponsor": "Eli Lilly and Company", "title": "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight", "primary_outcome": "Percent Change From Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT05929066" }, { "nct_id": "NCT07036172", "state": "overdue", "primary_completion_date": "2026-04", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "RECRUITING", "enrollment": "460", "sponsor": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.", "title": "Efficacy and Safety of Semaglutide Injection Vs WEGOVY\u00ae in Chinese Obese Patients", "primary_outcome": "The percentage change in body weight from baseline to week 44", "record_url": "https://clinicaltrials.gov/study/NCT07036172" }, { "nct_id": "NCT05574439", "state": "reached", "primary_completion_date": "2026-04-01", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P4", "status": "COMPLETED", "enrollment": "246", "sponsor": "Signe Torekov", "title": "Young Adults With Early-onset Obesity Treated With Semaglutide", "primary_outcome": "Change in BMI (weight in kg/height in m^2)", "record_url": "https://clinicaltrials.gov/study/NCT05574439" }, { "nct_id": "NCT06817356", "state": "reached", "primary_completion_date": "2026-03-19", "primary_completion_type": "ACTUAL", "drug": "mazdutide", "phase": "P2", "status": "COMPLETED", "enrollment": "308", "sponsor": "Eli Lilly and Company", "title": "A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder", "primary_outcome": "Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method", "record_url": "https://clinicaltrials.gov/study/NCT06817356" }, { "nct_id": "NCT07820111", "state": "reached", "primary_completion_date": "2026-03-17", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "159", "sponsor": "Zagazig University", "title": "Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial", "primary_outcome": "change in body weight at 3 and 6 months", "record_url": "https://clinicaltrials.gov/study/NCT07820111" }, { "nct_id": "NCT05803421", "state": "reached", "primary_completion_date": "2026-03-16", "primary_completion_type": "ACTUAL", "drug": "orforglipron", "phase": "P3", "status": "COMPLETED", "enrollment": "2749", "sponsor": "Eli Lilly and Company", "title": "A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk", "primary_outcome": "Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]", "record_url": "https://clinicaltrials.gov/study/NCT05803421" }, { "nct_id": "NCT06738979", "state": "reached", "primary_completion_date": "2026-03-07", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "408", "sponsor": "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.", "title": "A Clinical Study Comparing Semaglutide Injection and Wegovy\u00ae for Weight Management in Obese Subjects", "primary_outcome": "Percentage (%) of body weight loss", "record_url": "https://clinicaltrials.gov/study/NCT06738979" }, { "nct_id": "NCT06221969", "state": "reached", "primary_completion_date": "2026-03-04", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "1024", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor", "primary_outcome": "Change in glycated haemoglobin (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06221969" }, { "nct_id": "NCT04892199", "state": "overdue", "primary_completion_date": "2026-03-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "UNKNOWN", "enrollment": "104", "sponsor": "Anders Fink-Jensen, MD, DMSci", "title": "Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?", "primary_outcome": "The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c).", "record_url": "https://clinicaltrials.gov/study/NCT04892199" }, { "nct_id": "NCT06737042", "state": "reached", "primary_completion_date": "2026-02-27", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P2", "status": "COMPLETED", "enrollment": "326", "sponsor": "Gan and Lee Pharmaceuticals, USA", "title": "Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants", "primary_outcome": "Primary Objective", "record_url": "https://clinicaltrials.gov/study/NCT06737042" }, { "nct_id": "NCT06605703", "state": "reached", "primary_completion_date": "2026-02-05", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P4", "status": "COMPLETED", "enrollment": "226", "sponsor": "WW International Inc", "title": "A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)", "primary_outcome": "Percent body weight change at 12 weeks", "record_url": "https://clinicaltrials.gov/study/NCT06605703" }, { "nct_id": "NCT06235086", "state": "reached", "primary_completion_date": "2026-02-03", "primary_completion_type": "ACTUAL", "drug": "dulaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "632", "sponsor": "CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.", "title": "A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus", "primary_outcome": "Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment", "record_url": "https://clinicaltrials.gov/study/NCT06235086" }, { "nct_id": "NCT06287307", "state": "overdue", "primary_completion_date": "2026-02", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "UNKNOWN", "enrollment": "152", "sponsor": "Zuyderland Medisch Centrum", "title": "Semaglutide 2.4mg for Low Responders After Bariatric Surgery", "primary_outcome": "Weight change from start study at 3 months post operative until 15 months later", "record_url": "https://clinicaltrials.gov/study/NCT06287307" }, { "nct_id": "NCT07109700", "state": "overdue", "primary_completion_date": "2026-01-31", "primary_completion_type": "ESTIMATED", "drug": "dulaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "216", "sponsor": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.", "title": "A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin", "primary_outcome": "Change from baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT07109700" }, { "nct_id": "NCT06354660", "state": "reached", "primary_completion_date": "2026-01-22", "primary_completion_type": "ACTUAL", "drug": "retatrutide", "phase": "P3", "status": "COMPLETED", "enrollment": "537", "sponsor": "Eli Lilly and Company", "title": "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c) (%)", "record_url": "https://clinicaltrials.gov/study/NCT06354660" }, { "nct_id": "NCT06762314", "state": "reached", "primary_completion_date": "2026-01-20", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "114", "sponsor": "Mostafa Bahaa", "title": "Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes", "primary_outcome": "The primary outcome of this trial is the change in glycated haemoglobin from baseline after 3 months of treatment.", "record_url": "https://clinicaltrials.gov/study/NCT06762314" }, { "nct_id": "NCT06047548", "state": "reached", "primary_completion_date": "2026-01-20", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P3", "status": "COMPLETED", "enrollment": "441", "sponsor": "Eli Lilly and Company", "title": "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "primary_outcome": "Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period", "record_url": "https://clinicaltrials.gov/study/NCT06047548" }, { "nct_id": "NCT06643728", "state": "reached", "primary_completion_date": "2026-01-16", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "252", "sponsor": "Eli Lilly and Company", "title": "A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight", "primary_outcome": "Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT06643728" }, { "nct_id": "NCT06588283", "state": "reached", "primary_completion_date": "2026-01-08", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P3", "status": "COMPLETED", "enrollment": "281", "sponsor": "Eli Lilly and Company", "title": "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight", "primary_outcome": "Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction", "record_url": "https://clinicaltrials.gov/study/NCT06588283" }, { "nct_id": "NCT06037252", "state": "reached", "primary_completion_date": "2026-01-08", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "414", "sponsor": "Eli Lilly and Company", "title": "A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity", "primary_outcome": "Percent Change From Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT06037252" }, { "nct_id": "NCT04873050", "state": "overdue", "primary_completion_date": "2026-01-01", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "102", "sponsor": "Woman's", "title": "Treatment to Regress to Normoglycemia in Women with a Recent History of GDM", "primary_outcome": "Regression to normoglycemia", "record_url": "https://clinicaltrials.gov/study/NCT04873050" }, { "nct_id": "NCT05952882", "state": "overdue", "primary_completion_date": "2025-12-31", "primary_completion_type": "ESTIMATED", "drug": "liraglutide", "phase": "P3", "status": "UNKNOWN", "enrollment": "188", "sponsor": "M\u1ef9 \u0110\u1ee9c Hospital", "title": "Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility", "primary_outcome": "Absolute Body Weight (BW)", "record_url": "https://clinicaltrials.gov/study/NCT05952882" }, { "nct_id": "NCT06925334", "state": "overdue", "primary_completion_date": "2025-12-31", "primary_completion_type": "ESTIMATED", "drug": "liraglutide", "phase": "P4", "status": "ENROLLING_BY_INVITATION", "enrollment": "170", "sponsor": "Beijing Tsinghua Chang Gung Hospital", "title": "A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus", "primary_outcome": "Time to blood glucose compliance", "record_url": "https://clinicaltrials.gov/study/NCT06925334" }, { "nct_id": "NCT05877547", "state": "reached", "primary_completion_date": "2025-12-29", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "381", "sponsor": "Merck Sharp & Dohme LLC", "title": "A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)", "primary_outcome": "Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52", "record_url": "https://clinicaltrials.gov/study/NCT05877547" }, { "nct_id": "NCT06579105", "state": "reached", "primary_completion_date": "2025-12-19", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "406", "sponsor": "AstraZeneca", "title": "Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.", "primary_outcome": "Change in HbA1c", "record_url": "https://clinicaltrials.gov/study/NCT06579105" }, { "nct_id": "NCT06373146", "state": "reached", "primary_completion_date": "2025-12-15", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P2", "status": "COMPLETED", "enrollment": "392", "sponsor": "Eli Lilly and Company", "title": "A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity", "primary_outcome": "Mean Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT06373146" }, { "nct_id": "NCT06066528", "state": "reached", "primary_completion_date": "2025-12-12", "primary_completion_type": "ACTUAL", "drug": "survodutide", "phase": "P3", "status": "COMPLETED", "enrollment": "755", "sponsor": "Boehringer Ingelheim", "title": "A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight", "primary_outcome": "Percentage change in body weight from baseline to Week 76", "record_url": "https://clinicaltrials.gov/study/NCT06066528" }, { "nct_id": "NCT06131437", "state": "reached", "primary_completion_date": "2025-12-08", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "809", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight", "primary_outcome": "To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weight", "record_url": "https://clinicaltrials.gov/study/NCT06131437" }, { "nct_id": "NCT06176365", "state": "reached", "primary_completion_date": "2025-12-03", "primary_completion_type": "ACTUAL", "drug": "survodutide", "phase": "P3", "status": "COMPLETED", "enrollment": "274", "sponsor": "Boehringer Ingelheim", "title": "A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease", "primary_outcome": "Percentage change in body weight from baseline to Week 76", "record_url": "https://clinicaltrials.gov/study/NCT06176365" }, { "nct_id": "NCT06066515", "state": "reached", "primary_completion_date": "2025-12-02", "primary_completion_type": "ACTUAL", "drug": "survodutide", "phase": "P3", "status": "COMPLETED", "enrollment": "726", "sponsor": "Boehringer Ingelheim", "title": "A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight", "primary_outcome": "Percentage change in body weight from baseline to Week 76", "record_url": "https://clinicaltrials.gov/study/NCT06066515" }, { "nct_id": "NCT05708859", "state": "overdue", "primary_completion_date": "2025-12", "primary_completion_type": "ESTIMATED", "drug": "tirzepatide", "phase": "P4", "status": "RECRUITING", "enrollment": "120", "sponsor": "Matthew J. Budoff", "title": "Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT", "primary_outcome": "Reduction of total non-calcified coronary plaque volume", "record_url": "https://clinicaltrials.gov/study/NCT05708859" }, { "nct_id": "NCT05965908", "state": "reached", "primary_completion_date": "2025-11-30", "primary_completion_type": "ACTUAL", "drug": "liraglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "183", "sponsor": "Beni-Suef University", "title": "Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome", "primary_outcome": "Insulin Resistance (HOMA-IR)", "record_url": "https://clinicaltrials.gov/study/NCT05965908" }, { "nct_id": "NCT05989711", "state": "reached", "primary_completion_date": "2025-11-25", "primary_completion_type": "ACTUAL", "drug": "pemvidutide", "phase": "P2", "status": "COMPLETED", "enrollment": "212", "sponsor": "Altimmune, Inc.", "title": "IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)", "primary_outcome": "Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis", "record_url": "https://clinicaltrials.gov/study/NCT05989711" }, { "nct_id": "NCT06409130", "state": "reached", "primary_completion_date": "2025-11-21", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "270", "sponsor": "Novo Nordisk A/S", "title": "Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease", "primary_outcome": "Change in Enhanced Liver Fibrosis (ELF)", "record_url": "https://clinicaltrials.gov/study/NCT06409130" }, { "nct_id": "NCT06584916", "state": "reached", "primary_completion_date": "2025-11-21", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "376", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)", "primary_outcome": "Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5", "record_url": "https://clinicaltrials.gov/study/NCT06584916" }, { "nct_id": "NCT07163624", "state": "reached", "primary_completion_date": "2025-11-21", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "211", "sponsor": "The United Bio-Technology (Hengqin) Co., Ltd.", "title": "UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study", "primary_outcome": "Change From Baseline in HbA1c at Week 24", "record_url": "https://clinicaltrials.gov/study/NCT07163624" }, { "nct_id": "NCT06065540", "state": "reached", "primary_completion_date": "2025-11-19", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "2734", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor", "primary_outcome": "CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06065540" }, { "nct_id": "NCT06588296", "state": "reached", "primary_completion_date": "2025-11-18", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P3", "status": "COMPLETED", "enrollment": "279", "sponsor": "Eli Lilly and Company", "title": "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight", "primary_outcome": "Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction", "record_url": "https://clinicaltrials.gov/study/NCT06588296" }, { "nct_id": "NCT05931367", "state": "reached", "primary_completion_date": "2025-11-14", "primary_completion_type": "ACTUAL", "drug": "retatrutide", "phase": "P3", "status": "COMPLETED", "enrollment": "445", "sponsor": "Eli Lilly and Company", "title": "A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee", "primary_outcome": "Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score", "record_url": "https://clinicaltrials.gov/study/NCT05931367" }, { "nct_id": "NCT05610800", "state": "reached", "primary_completion_date": "2025-11-07", "primary_completion_type": "ACTUAL", "drug": "exenatide", "phase": "P2", "status": "COMPLETED", "enrollment": "140", "sponsor": "The University of Texas Health Science Center, Houston", "title": "Exenatide for Smoking Cessation and Prevention of Weight Gain", "primary_outcome": "Percentage of participants with 4-week continuous abstinence at 12 weeks post-target quit day as assessed by self-report timeline followback (TLFB) and verified by breath carbon monoxide (CO) level", "record_url": "https://clinicaltrials.gov/study/NCT05610800" }, { "nct_id": "NCT06693843", "state": "reached", "primary_completion_date": "2025-10-24", "primary_completion_type": "ACTUAL", "drug": "aleniglipron", "phase": "P2", "status": "COMPLETED", "enrollment": "230", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "title": "A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity", "primary_outcome": "Percent change in body weight from Baseline to Week 36", "record_url": "https://clinicaltrials.gov/study/NCT06693843" }, { "nct_id": "NCT05433584", "state": "reached", "primary_completion_date": "2025-10-21", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P4", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "780", "sponsor": "Eli Lilly and Company", "title": "A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes", "primary_outcome": "Change from Baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT05433584" }, { "nct_id": "NCT05726227", "state": "reached", "primary_completion_date": "2025-10-15", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "212", "sponsor": "Novo Nordisk A/S", "title": "A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight", "primary_outcome": "Group Kids: Change in body mass index (BMI)", "record_url": "https://clinicaltrials.gov/study/NCT05726227" }, { "nct_id": "NCT06309992", "state": "reached", "primary_completion_date": "2025-10-09", "primary_completion_type": "ACTUAL", "drug": "survodutide", "phase": "P3", "status": "COMPLETED", "enrollment": "218", "sponsor": "Boehringer Ingelheim", "title": "A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)", "primary_outcome": "Relative reduction in liver fat content of at least 30% from baseline to Week 48 (yes/no) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) [%]", "record_url": "https://clinicaltrials.gov/study/NCT06309992" }, { "nct_id": "NCT06804603", "state": "reached", "primary_completion_date": "2025-10-06", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "124", "sponsor": "Vanda Pharmaceuticals", "title": "A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use", "primary_outcome": "Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary.", "record_url": "https://clinicaltrials.gov/study/NCT06804603" }, { "nct_id": "NCT06660173", "state": "reached", "primary_completion_date": "2025-10-06", "primary_completion_type": "ACTUAL", "drug": "maridebart cafraglutide", "phase": "P2", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "409", "sponsor": "Amgen", "title": "A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)", "primary_outcome": "Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06660173" }, { "nct_id": "NCT05936151", "state": "reached", "primary_completion_date": "2025-10-01", "primary_completion_type": "ACTUAL", "drug": "retatrutide", "phase": "P2", "status": "COMPLETED", "enrollment": "146", "sponsor": "Eli Lilly and Company", "title": "A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "primary_outcome": "Change from Baseline in Glomerular Filtration Rate (mGFR)", "record_url": "https://clinicaltrials.gov/study/NCT05936151" }, { "nct_id": "NCT06559722", "state": "overdue", "primary_completion_date": "2025-10", "primary_completion_type": "ESTIMATED", "drug": "liraglutide", "phase": "P3", "status": "UNKNOWN", "enrollment": "510", "sponsor": "Tonghua Dongbao Pharmaceutical Co.,Ltd", "title": "A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes", "primary_outcome": "Change from baseline in HbA1c after 26 weeks of treatment", "record_url": "https://clinicaltrials.gov/study/NCT06559722" }, { "nct_id": "NCT06323174", "state": "reached", "primary_completion_date": "2025-10-01", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "189", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise", "primary_outcome": "Change in glycated haemoglobin (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06323174" }, { "nct_id": "NCT06410352", "state": "reached", "primary_completion_date": "2025-09-30", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P4", "status": "RECRUITING", "enrollment": "220", "sponsor": "University Medical Center, Kazakhstan", "title": "Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome", "primary_outcome": "Weight", "record_url": "https://clinicaltrials.gov/study/NCT06410352" }, { "nct_id": "NCT06662539", "state": "reached", "primary_completion_date": "2025-09-30", "primary_completion_type": "ACTUAL", "drug": "petrelintide", "phase": "P2", "status": "COMPLETED", "enrollment": "493", "sponsor": "Zealand Pharma", "title": "Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities", "primary_outcome": "Percent change from baseline in body weight to Week 28", "record_url": "https://clinicaltrials.gov/study/NCT06662539" }, { "nct_id": "NCT06192108", "state": "reached", "primary_completion_date": "2025-09-26", "primary_completion_type": "ACTUAL", "drug": "orforglipron", "phase": "P3", "status": "COMPLETED", "enrollment": "962", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin", "primary_outcome": "Change From Baseline in HbA1c [Noninferiority Analysis]", "record_url": "https://clinicaltrials.gov/study/NCT06192108" }, { "nct_id": "NCT06131372", "state": "reached", "primary_completion_date": "2025-09-24", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "626", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo", "primary_outcome": "Change in urinary albumin-to-creatinine ratio (UACR)", "record_url": "https://clinicaltrials.gov/study/NCT06131372" }, { "nct_id": "NCT06326047", "state": "reached", "primary_completion_date": "2025-09-19", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P2", "status": "COMPLETED", "enrollment": "299", "sponsor": "Novo Nordisk A/S", "title": "A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes", "primary_outcome": "Change in Glycated haemoglobin (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06326047" }, { "nct_id": "NCT06184568", "state": "reached", "primary_completion_date": "2025-09-17", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "349", "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "title": "A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity", "primary_outcome": "Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and \u226510% weight loss", "record_url": "https://clinicaltrials.gov/study/NCT06184568" }, { "nct_id": "NCT04777396", "state": "reached", "primary_completion_date": "2025-09-16", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "1840", "sponsor": "Novo Nordisk A/S", "title": "A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)", "primary_outcome": "Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score", "record_url": "https://clinicaltrials.gov/study/NCT04777396" }, { "nct_id": "NCT04777409", "state": "reached", "primary_completion_date": "2025-09-15", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "1840", "sponsor": "Novo Nordisk A/S", "title": "A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)", "primary_outcome": "Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score", "record_url": "https://clinicaltrials.gov/study/NCT04777409" }, { "nct_id": "NCT06109311", "state": "reached", "primary_completion_date": "2025-09-15", "primary_completion_type": "ACTUAL", "drug": "orforglipron", "phase": "P3", "status": "COMPLETED", "enrollment": "546", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor", "primary_outcome": "Change From Baseline in Hemoglobin A1c (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06109311" }, { "nct_id": "NCT06771115", "state": "reached", "primary_completion_date": "2025-09-10", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "175", "sponsor": "Zomagen Biosciences Ltd.", "title": "Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity", "primary_outcome": "Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)", "record_url": "https://clinicaltrials.gov/study/NCT06771115" }, { "nct_id": "NCT06323161", "state": "reached", "primary_completion_date": "2025-09-09", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "274", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin", "primary_outcome": "Change in Glycated Haemoglobin (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06323161" }, { "nct_id": "NCT05630586", "state": "overdue", "primary_completion_date": "2025-09", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2", "status": "RECRUITING", "enrollment": "380", "sponsor": "Aarhus University Hospital", "title": "Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke", "primary_outcome": "Modified Ranking Scale", "record_url": "https://clinicaltrials.gov/study/NCT05630586" }, { "nct_id": "NCT06339086", "state": "overdue", "primary_completion_date": "2025-08-30", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P3", "status": "UNKNOWN", "enrollment": "478", "sponsor": "Chengdu Brilliant Pharmaceutical Co., Ltd.", "title": "Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes", "primary_outcome": "Change in HbA1c", "record_url": "https://clinicaltrials.gov/study/NCT06339086" }, { "nct_id": "NCT06604624", "state": "reached", "primary_completion_date": "2025-08-27", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "462", "sponsor": "CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.", "title": "Semaglutide in Treatment of Obesity", "primary_outcome": "Relative percentage change in body weight from baseline at 44 weeks of treatment", "record_url": "https://clinicaltrials.gov/study/NCT06604624" }, { "nct_id": "NCT06045221", "state": "reached", "primary_completion_date": "2025-08-22", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "1698", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin", "primary_outcome": "Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide]", "record_url": "https://clinicaltrials.gov/study/NCT06045221" }, { "nct_id": "NCT05872620", "state": "reached", "primary_completion_date": "2025-08-08", "primary_completion_type": "ACTUAL", "drug": "orforglipron", "phase": "P3", "status": "COMPLETED", "enrollment": "1613", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes", "primary_outcome": "Percent Change From Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT05872620" }, { "nct_id": "NCT07092618", "state": "overdue", "primary_completion_date": "2025-08", "primary_completion_type": "ESTIMATED", "drug": "semaglutide", "phase": "P2/P3", "status": "RECRUITING", "enrollment": "150", "sponsor": "AgelessRx", "title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation", "primary_outcome": "Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent)", "record_url": "https://clinicaltrials.gov/study/NCT07092618" }, { "nct_id": "NCT05895643", "state": "reached", "primary_completion_date": "2025-07-31", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P2", "status": "COMPLETED", "enrollment": "108", "sponsor": "Psychiatric Centre Rigshospitalet", "title": "Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?", "primary_outcome": "Change in heavy drinking days", "record_url": "https://clinicaltrials.gov/study/NCT05895643" }, { "nct_id": "NCT06214741", "state": "reached", "primary_completion_date": "2025-07-29", "primary_completion_type": "ACTUAL", "drug": "survodutide", "phase": "P3", "status": "COMPLETED", "enrollment": "307", "sponsor": "Boehringer Ingelheim", "title": "A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight", "primary_outcome": "Percentage change in body weight from baseline to Week 52", "record_url": "https://clinicaltrials.gov/study/NCT06214741" }, { "nct_id": "NCT05869903", "state": "reached", "primary_completion_date": "2025-07-25", "primary_completion_type": "ACTUAL", "drug": "orforglipron", "phase": "P3", "status": "ACTIVE_NOT_RECRUITING", "enrollment": "3127", "sponsor": "Eli Lilly and Company", "title": "A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities", "primary_outcome": "Percent Change From Baseline in Body Weight (Primary Treatment Period)", "record_url": "https://clinicaltrials.gov/study/NCT05869903" }, { "nct_id": "NCT06482112", "state": "reached", "primary_completion_date": "2025-06-27", "primary_completion_type": "ACTUAL", "drug": "efinopegdutide", "phase": "P2", "status": "COMPLETED", "enrollment": "124", "sponsor": "Merck Sharp & Dohme LLC", "title": "Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)", "primary_outcome": "Mean Relative Reduction From Baseline in Liver Fat Content at Week 28", "record_url": "https://clinicaltrials.gov/study/NCT06482112" }, { "nct_id": "NCT06164873", "state": "overdue", "primary_completion_date": "2025-06-27", "primary_completion_type": "ESTIMATED", "drug": "mazdutide", "phase": "P3", "status": "UNKNOWN", "enrollment": "462", "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "title": "A Study of IBI362 9 mg in Chinese Adults With Obesity", "primary_outcome": "Percent Change from Baseline in Body Weight", "record_url": "https://clinicaltrials.gov/study/NCT06164873" }, { "nct_id": "NCT06828055", "state": "reached", "primary_completion_date": "2025-06-24", "primary_completion_type": "ACTUAL", "drug": "VK2735", "phase": "P2", "status": "COMPLETED", "enrollment": "280", "sponsor": "Viking Therapeutics, Inc.", "title": "VK2735 for Weight Management Phase 2 (Venture Oral Dosing)", "primary_outcome": "Percent (relative) change from baseline in body weight after 13 weeks of treatment", "record_url": "https://clinicaltrials.gov/study/NCT06828055" }, { "nct_id": "NCT05931380", "state": "reached", "primary_completion_date": "2025-06-19", "primary_completion_type": "ACTUAL", "drug": "orforglipron", "phase": "P3", "status": "COMPLETED", "enrollment": "238", "sponsor": "Eli Lilly and Company", "title": "A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease", "primary_outcome": "Percent Change From Baseline in Body Weight at Week 72", "record_url": "https://clinicaltrials.gov/study/NCT05931380" }, { "nct_id": "NCT05035082", "state": "reached", "primary_completion_date": "2025-06-18", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P4", "status": "COMPLETED", "enrollment": "1018", "sponsor": "Novo Nordisk A/S", "title": "A Research Study Comparing RYBELSUS\u00ae to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)", "primary_outcome": "Change in Glycated Haemoglobin (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT05035082" }, { "nct_id": "NCT04255433", "state": "reached", "primary_completion_date": "2025-06-12", "primary_completion_type": "ACTUAL", "drug": "tirzepatide", "phase": "P3", "status": "COMPLETED", "enrollment": "13299", "sponsor": "Eli Lilly and Company", "title": "A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes", "primary_outcome": "Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]", "record_url": "https://clinicaltrials.gov/study/NCT04255433" }, { "nct_id": "NCT06010004", "state": "reached", "primary_completion_date": "2025-06-05", "primary_completion_type": "ACTUAL", "drug": "orforglipron", "phase": "P3", "status": "COMPLETED", "enrollment": "401", "sponsor": "Eli Lilly and Company", "title": "A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes", "primary_outcome": "Number of Participants With Treatment Emergent Adverse Events (TEAEs)", "record_url": "https://clinicaltrials.gov/study/NCT06010004" }, { "nct_id": "NCT07374445", "state": "reached", "primary_completion_date": "2025-06-01", "primary_completion_type": "ACTUAL", "drug": "liraglutide", "phase": "P4", "status": "COMPLETED", "enrollment": "100", "sponsor": "The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School", "title": "Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery", "primary_outcome": "Change in %TWL from baseline to endpoint across patient groups", "record_url": "https://clinicaltrials.gov/study/NCT07374445" }, { "nct_id": "NCT06269107", "state": "reached", "primary_completion_date": "2025-05-27", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "485", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)", "primary_outcome": "Change in glycated haemoglobin (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06269107" }, { "nct_id": "NCT06161844", "state": "reached", "primary_completion_date": "2025-05-14", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "506", "sponsor": "CSPC ZhongQi Pharmaceutical Technology Co., Ltd.", "title": "Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus", "primary_outcome": "Change from baseline to week 32 in glycosylated haemoglobin (HbA1c)", "record_url": "https://clinicaltrials.gov/study/NCT06161844" }, { "nct_id": "NCT05548647", "state": "reached", "primary_completion_date": "2025-05-12", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P4", "status": "COMPLETED", "enrollment": "120", "sponsor": "University of Pennsylvania", "title": "Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects", "primary_outcome": "Study 1 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)", "record_url": "https://clinicaltrials.gov/study/NCT05548647" }, { "nct_id": "NCT04596631", "state": "reached", "primary_completion_date": "2025-04-29", "primary_completion_type": "ACTUAL", "drug": "semaglutide", "phase": "P3", "status": "COMPLETED", "enrollment": "132", "sponsor": "Novo Nordisk A/S", "title": "A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes", "primary_outcome": "Change From Baseline (Week 0) to Week 26 in Glycosylated Haemoglobin (HbA1c)- Percentage Point", "record_url": "https://clinicaltrials.gov/study/NCT04596631" } ] }